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CHAPTER 1 
 Introduction  
 
1.1. The Obesity Pandemic  
 Obesity rate in the US has doubled in the last two decades with more than one 
third of adults and almost 17% of children and adolescents being obese [1, 2]. There 
has been a synchronized increase in obesity rates in almost all countries, likely due to 
the increase in affordable processed food worldwide which in turn has created a global 
overconsumption of energy [3]. While public health initiatives to manage the 
prerequisites of obesity are crucial, treating its drawbacks is currently a major global 
concern. This pandemic has shown a detrimental impact on health-related quality of life 
of affected individuals due to obesity-related comorbidity, specifically cardiovascular 
disease, type-2 diabetes, obesity-related cancers, osteoarthritis, and psychological 
disturbance [4]. Needless to say, the resulting economic burden has expanded 
dramatically [5, 6]. 
1.2. Obesity, Oxidative Stress and Diabetes 
Excessive body fat is directly correlated with an increased generation of systemic 
reactive oxygen species coupled with a significant reduction in the body’s antioxidant 
capacity [7]. The state of chronic inflammation and oxidative stress that is thus created 
is believed to play a role in promoting obesity-related complications [8, 9]. In fact, these 
impairments are thought to directly lead to an inhibition of insulin responses, hence 
giving rise to insulin resistance and type-2 diabetes [7, 10]. Although the exact 
mechanism linking oxidative stress with altered insulin signaling is not fully understood, 
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there is a consensus that impaired insulin signaling is one of the outcomes of oxidative 
stress, likely through multiple pathways (Fig. 1.1) [11]. Another common metabolic 
attribute linked to obesity is hyperglycemia [8, 12], which in turn has been associated 
with the precipitation of oxidative stress and inflammation [13, 14], thus further 
promoting diabetes and its complications [15-17]. Therefore, oxidative stress appears to 
partake in both the initiation and the progression of diabetes and its related 
complications [11].  
 
  
Fig. 1.1. The Effect of Chronic Oxidative Stress on the Insulin Signaling Pathway. 
Adapted from Rains et al, Free Radic Biol Med. 2011. 
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1.3. Diabetes in the 21st Century 
Given the above stated facts, it is of no surprise that the prevalence of diabetes 
has risen at an alarming rate (Fig. 1.2). Diabetes currently affects 25.8 million people, 
that is 8.3% of the U.S. population [18], a number that is projected to double or triple by 
2050 [19]. In addition, based on fasting blood glucose or glycated hemoglobin (HbA1c) 
levels, an estimated 79 million American adults have prediabetes and therefore an 
increased risk of developing type-2 diabetes and other chronic conditions [18]. 
Particularly disturbing is the significant increase in the prevalence of type-2 diabetes 
among children and adolescents, making it no longer an adult-only disease [20]. The 
diabetes epidemic has become a massive health burden significantly decreasing quality 
of life and increasing morbidity and mortality among Americans, all at a huge economic 
cost [18, 21]. The aforesaid statistics are mostly based on an expanding prevalence of 
type-2 diabetes, a condition depicted by insulin resistance and ß-cell failure with an 
underlying genetic propensity profoundly influenced by lifestyle and diet [22]. This form 
of diabetes accounts for about 90-95% of diabetics and begins with a state of slowly 
progressing hyperglycemia [23]. Patients are at an increased risk for microvascular and 
macrovascular complications which in turn lead to disability and eventually death. In 
terms of microvascular complications, they typically tend to develop retinopathy, 
neuropathy and nephropathy especially at advanced stages of the disease [24]. In fact, 
diabetes is the leading cause of blindness and non-traumatic lower limb amputations 
among US adults, and accounts for a considerable percentage of end-stage renal 
disease occurrences [18]. In terms of macrovascular disease, the incidence of 
cardiovascular disease and stroke increases significantly with diabetes, due to high 
levels of circulating glucose in the blood 
noted on 68% and 16% of diabetes
respectively. The total estimated 
2007, and medical expenditures among diabetics were estimated to be around 2.3 
times higher than those of non
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. Age-adjusted Prevalence of Obesity and Diagnosed Diabetes Among U.S
Adults Aged 18 Years or Older. Source: 
http://www.cdc.gov/diabetes/statistics
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[24]. In 2004, heart disease and stroke were 
-related death certificates among US seniors, 
cost of diabetes in the US was around $175 billion in 
-diabetics  [18]. 
CDC’s Division of Diabetes Translation. 
. 
. 
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1.4. Conventional Management of Diabetes 
 Anti-hyperglycemic therapy entails two aspects of treatment: lifestyle 
modifications and pharmaceutical interventions, with the latter being the major focus in 
glycemic control. Lifestyle interventions are comprised of dietary and physical activity 
regimens that promote weight loss through controlling the intake and expenditure of 
energy resulting in better glycemic control [25]. In terms of pharmaceutical agents, the 
biguanide metformin is the most commonly used first-line drug for type 2 diabetes. It is 
an insulin sensitizer that mainly reduces hepatic glucose production [25, 26]. A less 
common class of insulin sensitizers, thiazolidinediones, reduce blood glucose levels by 
improving insulin sensitivity in skeletal muscle and reducing hepatic glucose output [27]. 
Insulin secretion from pancreatic ß-cells may be stimulated by insulin secretagogues, 
namely sulfonylureas and meglitinides. A newer class of insulin secretagogues, the 
injectable glucagon-like peptide-1 (GLP-1) receptor agonists, were introduced recently 
and are focused on the incretin physiology in stimulating pancreatic insulin release [28]. 
When oral agents are contraindicated or become insufficient, insulin replacement 
therapy is typically required [29]. Treatment regimens vary among patients and are 
often modified based on the body’s response and disease progression. 
1.5. Limitations in Diabetes Management 
 Conventional anti-hyperglycemic agents seem to be insufficient to contain the 
widespread problem of diabetes and side effects often limit treatment choices [30, 31]. 
The most commonly prescribed oral therapies for type-2 diabetes, metformin and 
sulfonylureas, are successful in initial reduction in blood glucose and complication rates. 
However, they are often unable to provide durable glycemic control, resulting in the 
6 
 
 
need for complicated treatment regimens [25]. Additionally, hypoglycemia and weight 
gain have been reported with sulfonylureas use [32]. Thiazolidinediones have become 
limited by their association with serious side effects such as weight gain, fluid retention 
and bone loss [32, 33]. Despite being the most effective treatment, insulin is associated 
with weight gain, hypoglycemia [30] and considerable economic costs [34]. Even newer 
agents carry concerns. For instance, GLP-1 receptor agonists are accompanied by 
nausea and vomiting in addition to an increased risk of pancreatitis [35]. Therefore, 
there is an urgent need for alternative therapeutic strategies that will provide a broader 
range of choices while addressing safety and patient-tailored treatment. 
1.6. Targeting Postprandial Hyperglycemia 
 While the traditional goal in managing diabetes is to control fasting blood glucose 
and HbA1c levels, treatment of postprandial hyperglycemia has become a compelling 
target to improve overall glycemic control [36-40]. Postprandial hyperglycemia develops 
early in the course of type-2 diabetes when insulin secretion becomes compromised 
[39]. It has been accused of the induction of glucose toxicity and ß-cell function 
deterioration which can ultimately give rise to an irreversible state of diabetes [39, 41]. It 
is also an independent risk factor for the development of cardiovascular disease, the 
leading cause of morbidity and mortality among diabetics [42, 43]. Postprandial 
hyperglycemia is linked to the amount of consumed starch and its rate of digestion, 
being the chief source of blood glucose [36]. Reducing the amount and rate of 
carbohydrate digestion and absorption can be an effective approach for postprandial 
hyperglycemia treatment [44-46]. This can be achieved by inhibiting starch hydrolyzing 
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enzymes in the digestive tract [46-50], perhaps through the use of food-derived 
phytochemicals [36, 50].  
1.7. Control of Carbohydrate Digestion: α-Glucosidase Inhibition 
 Mammalian starch digestion takes place primarily in the small intestine through 
the action of α-amylase, resulting in both linear maltose and branched isomaltose 
oligosaccharides that are additionally hydrolyzed by α-glucosidases to yield glucose [50-
52]. Natural as well as synthetic compounds are known to reduce postprandial 
hyperglycemia by inhibiting major carbohydrate digesting enzymes in the small 
intestine, such as α-glucosidase (Fig. 1.3) [53-55]. Inhibition of α-glucosidases has been 
shown to be effective in both preventing and treating type-2 diabetes through reducing 
postprandial hyperglycemia [38, 52, 55]. However, commercial inhibitors that have been 
used for diabetes treatment (i.e. Acarbose) were found to exhibit a non-specific 
inhibition of α-amylase, resulting in excessive accumulation of undigested carbohydrate 
in the colon, thus generating undesirable gastrointestinal side effects [36, 56, 57]. 
Research aiming at identifying novel inhibitors has increased in the last three decades. 
For instance, numerous plant extracts rich in polyphenols and phenolic compounds 
isolated from plants have been investigated and reported to be powerful inhibitors of 
carbohydrate hydrolyzing enzymes [58-60].  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
1.8. Natural Products in Drug Discovery
 Natural products, either as extracts or as pure compounds, possess an immense 
potential as new drug leads due to their exceptional chemical diversity 
sources continue to serve as an inexhaustible source of bioactive compounds 
Concurrently, consumer demand for alternative treatments is persistently increasing. In 
fact, the abundance of plant compounds 
unconventional therapy is becoming a common choice among many consumers. 
Nevertheless, the purity of these substances is uncertain and available information 
regarding dosage is limited 
medicines, the high cost of currently available synthetic medicines, and adverse side
effects of pharmaceuticals have together created a need to further develop natural 
products. The screening of natural preparations has become pivotal in the discovery of 
Fig. 1.3. Simplified Schematic of Carbohydrate Digestion and Absorption in the Small 
Intestine; Inhibition of α-Glucosidases 
 
8 
 
 
  
is customary in natural food stores, and 
[62, 63]. The public perception of gentleness of natural 
Glucose
Absorption
Oligo-saccharides
(α-Glucosidases)
Starch
(α-Amylase)
to Reduce Glucose Absorption. 
[61]. Plant 
[62]. 
-
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various drugs [64]. For instance, in a screening for natural, food-derived α-glucosidase 
inhibitors, we identified a red grape pomace extract to be the most potent in inhibiting α-
glucosidases, among over 300 extracts and compounds tested [31]. Further 
investigation yielded promising specificity and effectiveness data in vitro and in vivo, 
respectively [31, 65]. However, comparison of a wider range of grape pomaces and 
identification of the components responsible for the inhibitory activity have not been 
performed, to our knowledge. 
1.9. Grape-Derived Bioactives and Grape Pomace 
Grapes, namely red wine cultivars, are known to be among the highest 
antioxidant containing fruits [66, 67] and their pomaces have particularly been found to 
be rich in polyphenols and other antioxidants [68-70]. Grape pomace is the solid 
remains of grape following pressing for juice. It consists of the dry pulp with intact skin, 
seeds and stem, thus retaining a considerable amount of functional compounds that 
normally reside in these parts [71, 72]. Yet, grape pomace is considered a waste 
byproduct generated in the winemaking industry [73]. As a result, a waste-management 
issue arises from the accumulation of big loads of this byproduct annually [74]. The very 
limited uses of grape pomace include recycling as animal feed, organic fertilizers, and 
manure [31]. Meanwhile, grapes continue to be studied and recognized as a natural 
source of prominent bioactive compounds with potential health promoting and disease 
preventing properties [66, 68, 75]. For instance, remarkable amounts of polyphenolic 
compounds are found in grapes, grape seed extracts and wine [75-78]. Due to their 
ability to inhibit peroxidation chain reactions, dietary antioxidants have been associated 
10 
 
 
with a reduced risk of type 2 diabetes [79, 80]. However, literature on the potential of 
grape pomace as an alternative bioresource for diabetes management is very minimal.  
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CHAPTER 2 
BACKGROUND, HYPOTHESIS AND SPECIFIC AIMS 
 
Objective and Significance of the Study 
 Given the overwhelming rise in diabetes, it is imperative to explore novel 
approaches to prevent and control it. The current research evaluated the anti-diabetic 
potential of a selection of six red wine grape pomaces by determining their α-
glucosidase inhibiting and antioxidant activities. After selecting the most potent variety, 
we isolated and identified the components responsible for the inhibiting activity, studied 
their specificity and dose response, and determined their stability, cytotoxicity and 
antioxidant capacity. This research may provide a foundation for the future development 
of a food-derived α-glucosidase inhibitor from grape pomace for preventing and treating 
diabetes, thus establishing a novel, safe dietary anti-diabetic strategy. 
Hypothesis 
We hypothesized that antioxidant rich red wine grape pomace contains 
components that possess an anti-diabetes functional food potential through specifically 
inhibiting intestinal α-glucosidases. 
To test our hypothesis, we pursued 3 studies as highlighted next. 
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STUDY 1: To Identify a Specific Grape Variety with Anti-Diabetes Functional Food 
Potential through α-Glucosidase-Inhibiting and Antioxidant Capacities (Fig. 2.1). 
Screening of plant-derived compounds for biological activity usually begins with 
an initial screening involving crude extracts of multiple plants or varieties of a plant [81]. 
α-glucosidases play a significant role in carbohydrate digestion and therefore 
postprandial blood glucose, a target for diabetes management [82]. The comparison of 
the α-glucosidase inhibitory potential of several crude grape pomace extracts allows the 
identification of the grape variety that is potentially rich in the inhibiting compounds.  
Therefore, six red wine grape varieties were selected for screening: 
Chambourcin (hybrid), Merlot (Vitis vinifera), Norton (Vitis aestivalis), Petit Verdot (Vitis 
vinifera), Syrah (Vitis vinifera) and Tinta Cão (Vitis vinifera), and α-glucosidase inhibition 
assay was utilized to compare their inhibiting potential. 
Additionally, numerous health protective functions have been attributed to 
antioxidants over the last few decades [75, 83, 84], suggesting that a bioactivity 
exhibited by a grape extract may be related to its antioxidant content. A review of 
literature on plant-derived α-glucosidase enzyme inhibitors indicates that known 
antioxidant compounds such as polyphenols, flavonoids and others have exhibited 
inhibitory activity in vitro [82, 85]. This brought about the need to investigate and 
compare the antioxidant makeup of our 6 grape varieties. Total Phenolic Content (TPC) 
assay is a popular method for quantifying antioxidants in a sample, as gallic acid 
equivalents [86]. Antioxidant capacity is usually further assessed by evaluating the 
sample’s ability to scavenge free radicals. Two assays commonly serve this purpose. 
13 
 
 
2,2-Diphenyl-1-picrylhydrazyl (DPPH) Radical Scavenging Assay [87] and Oxygen 
Radical Absorbance Capacity (ORAC) Assay with 2,2’-azobis(2-amidino-propane) 
dihydrochloride (AAPH) as the free radical generator [88]. Finally, inference on 
individual antioxidants in samples can be obtained via High Performance Liquid 
Chromatography (HPLC) profiling using known standards for comparison [89, 90].  
Hence, the abovementioned universal antioxidant assays were employed to 
quantify the antioxidant content while HPLC profile comparison allowed the detection of 
major differences as well as specific antioxidant compounds. 
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Fig. 2.1. Schematic of the Study Design for Study 1. 
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Functional Food Potential 
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STUDY 2: To Isolate and Identify Grape Pomace Components with α-glucosidase 
Inhibiting Activity via Bioactivity-Guided Fractionation (Fig. 2.2). 
A crude plant extract is a complex combination of bioactive compounds and 
phytochemicals, out of which only one or a few are responsible for the functional 
property of interest. Separation hence poses a challenge, usually involving various 
steps and multiple fractionation techniques [91]. Liquid-liquid extraction is a helpful initial 
step to break down the crude extract into parts based on their relative solubility in two 
different immiscible liquids [92]. When an active fraction is identified through bioassay, a 
separation plan is made based on the predicted characteristics inferred from partition, 
such as polarity, solubility, etc. Column chromatography is a popular method used to 
purify individual chemical compounds from complex mixtures [93].  
Therefore, the active grape pomace extract (GPE) was separated into fractions 
via liquid-liquid extraction and sub-fractions via column chromatography on a bioactivity 
guided fractionation basis to select the most active GPE sub-fraction. 
Column chromatography often generates simple fractions of unknown 
concentrations. A sensitive purification and quantification technique must hence follow. 
High Performance Liquid Chromatography (HPLC) is a powerful analytical tool that is 
usually the method of choice [94]. The determination of the chemical structure and 
formula of the isolated compound is then achieved via combinatorial chemistry, utilizing 
compound libraries. Integration of mass spectrometry (MS) and nuclear magnetic 
resonance (NMR) spectral data is the gold standard for structure verification in 
analytical chemistry [95].  
16 
 
 
 Compounds within the active sub-fraction were then separated and purified using 
column chromatography and HPLC and active compounds were selected by bioassay. 
NMR and MS were employed to characterize the active compounds. 
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Fig. 2.2. Schematic of the Study Design for Study 2. 
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Study 3: To Determine the Applicability of the Isolated Grape Pomace Component 
as a Natural Inhibitor of α-Glucosidases (Fig. 2.3). 
The process of drug development requires specific measures of mode of action 
and effectiveness prior to the procession to toxicological, pre-clinical and clinical testing. 
Mammalian intestinal α-glucosidase enzyme complex is comprised of three enzymes: 
sucrase, maltase and isomaltase, responsible for the digestion of sucrose, maltose and 
isomaltose, respectively [96]. It is necessary to identify which enzyme(s) in the complex 
is/are inhibited by the tested GPE components. Also, it has been reported that enzymes 
falling under the glycoside hydrolase family 13 such as α-amylase (EC 3.2.1.1) and α-
glucosidase (EC 3.2.1.20) share a common reaction mechanism and several short 
conserved sequences [97], which is why a non-specific inhibitor will likely inhibit both 
enzymes. α-Amylase inhibition by our compound must be ruled out. It is also essential 
to understand whether the observed bioactivity is dose-dependent. Lastly, it is important 
to evaluate the antioxidant capacity of the isolated compound to draw possible relations 
between α-glucosidase inhibition and antioxidant activity, and to understand the 
compound’s scope of bioactivity. 
For the above reasons, the active component’s enzyme inhibitory activity was 
tested against α-amylase and three individual α-glucosidases to identify and verify 
specificity, and antioxidant assays were employed to evaluate the antioxidant activity of 
the active compound. 
The problem of instability is often encountered with natural medicines. In the 
course of development of an herbal drug, the determination of stability of the drug in the 
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proposed active form is essential. Stability can be affected by environmental factors 
such as temperature, light, air and humidity. Intrinsic factors such as particle size, pH, 
and solvent properties can also have a significant impact on stability [98]. Hence, heat 
treatment and pH treatment are required to determine if the product has potential use as 
a commercial bioactive applicable to food products. Another necessary safety measure 
is cytotoxicity studies. Given the fact that plants have been eaten and used in traditional 
medicine for centuries, it is not uncommon to believe that all compounds derived from 
natural sources are safe for human consumption. However, an isolated active 
compound requires testing to ensure it is safe in pure form. 
The effect of heat treatment on the activity of the active component was 
assessed via bioassay. Similarly, bioassay was used to observe activity under various 
pH levels. The inhibitory activity of the isolated compound was also assessed via 
bioassay following storage under various conditions for a number of months. Lastly, the 
compound was tested for cytotoxicity using a normal animal cell line.  
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Fig. 2.3. Schematic of the Study Design for Study 3.  
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Abstract 
Dietary antioxidants have been associated with a reduced risk of type 2 diabetes. 
Grape pomace contains considerable amounts of polyphenols and it has been reported 
that grape pomace also exhibits specific inhibitory activity against alpha- glucosidases. 
This study aims to investigate the anti-diabetes potential of Chambourcin, Merlot, 
Norton, Petit Verdot, Syrah and Tinta Cão red wine grape pomaces by assessing their 
rat intestinal α-glucosidase inhibiting activity and antioxidant properties as well as their 
relationship. Among the selected pomaces, Tinta Cão, Syrah and Merlot extracts were 
the most potent inhibitors of α-glucosidase. These three varieties also appeared to have 
the highest respective total phenolic content. Chambourcin, Merlot and Tinta Cão 
exhibited the highest DPPH radical scavenging capacity, while Tinta Cão exceeded all 
other varieties in oxygen radical (AAPH) absorbing capacity. A strong positive 
correlation was observed between these results, suggesting that the α-glucosidase 
inhibiting potency of grape pomace extracts may be related to their richness in 
antioxidants. The phenolic compounds in the extracts were further purified and profiled 
using HPLC, and major differences in the concentrations of the profiled antioxidants 
were detected. However, none of these antioxidants individually was able to inhibit 
intestinal α-glucosidases in bioassay.  Red grape pomace, namely Tinta Cão, appears 
to be a promising functional food for the future development of a food-derived α-
glucosidase inhibitor for preventing and treating diabetes. 
 
Key words: Grape Pomace; Antioxidant; α-Glucosidase; Diabetes 
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Introduction 
The prevalence of obesity in the US has magnified in the last 20 years [2]. The 
state of chronic inflammation and oxidative stress that obesity has been associated with 
is believed to play a role in promoting obesity-related complications such as insulin 
resistance and type-2 diabetes [8, 9]. Another common metabolic attribute linked to 
obesity is hyperglycemia [8, 12], which in turn has been associated with the precipitation 
of oxidative stress and inflammation [13, 14], thus further promoting diabetes and its 
complications [15-17]. It is hence of no surprise that diabetes currently affects 25.8 
million people in the U.S. and the number of Americans with prediabetes is on the rise. 
The costs associated with diabetes and its consequences have become a significant 
burden in the American society [18].  
Type-2 diabetes is a chronic condition characterized by insulin resistance and ß-
cell failure resulting from lifestyle habits that interact with an underlying genetic 
susceptibility [22]. Given the overwhelming rise in this disease, it is imperative to 
explore novel approaches to prevent and control it, particularly in the light of the side 
effects and limited long-term durability associate with conventional anti-hyperglycemic 
agents [30]. Inhibition of α-glucosidases has been shown to be effective in both 
preventing and treating type-2 diabetes through reducing postprandial hyperglycemia 
[38, 55]. However, commercial inhibitors often come with gastrointestinal side effects 
due to their non-specific inhibitory activity [56, 57]. This necessitates the search for 
alternatives. Meanwhile, plant sources continue to serve as an inexhaustible source of 
bioactive compounds [62]. In a screening for natural, food-derived α-glucosidase 
inhibitors, we identified a red grape pomace extract possessing specific α-glucosidase 
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inhibitory activity [31]. However, comparison of a wider range of grape pomaces and 
obtaining inference on the components responsible for the inhibitory activity have not 
been achieved, to our knowledge. 
Grape pomace, the solid remains of grape after pressing, is commonly 
considered a waste byproduct generated in the winemaking industry [73]. On the other 
hand, grapes and wines are widely acknowledged as an important source of 
antioxidants, namely polyphenolic compounds such as flavanols, catechins, 
anthocyanins, and proanthocyanidins [75-78]. Since grape pomace is chiefly comprised 
of the skins and seeds, it is surmised that this biomass is a rich source of antioxidants 
[68, 69, 71]. While the literature associates dietary antioxidants with a reduced risk of 
type 2 diabetes [79, 80], it provides very limited information on the potential of grape 
pomace as an alternative bioresource for diabetes management.  
The aim of this study is to evaluate the anti-diabetic potential of a selection of six 
red wine grape pomaces by determining their α-glucosidase inhibiting and antioxidant 
activities as well as their relationship. This research may lay the foundation for the 
future development of a safe, food-derived α-glucosidase inhibitor from grape pomace 
for preventing and treating type 2 diabetes. 
MATERIALS AND METHODS 
Materials 
The organic solvents for grape pomace extraction and HPLC analysis were 
HPLC grade (Fisher Scientific, Atlanta, GA).  Intestinal acetone powders from rat, 4-
nitrophenyl-α-D-glucopyranoside (pNPG), Folin–Ciocalteu reagent, gallic acid, 2,2-Di(4-
tert-octylphenyl)-1-picrylhydrazyl (DPPH) and phenolic standards including caffeic acid, 
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delphinidin chloride, gallic acid, malvin chloride, malvidin chloride, quercetin hydrate and 
quercetin 3-O-glucoside were purchased from Sigma-Aldrich (St. Louis, MO). 2,2′-
Azobis(2-amidinopropane) dihydrochloride (AAPH) was purchased from Wako 
Chemicals USA, Inc. (Richmond, VA). Acarbose and other phenolic standards including 
catechin, epicatechin gallate, kaempferol, myricetin and resveratrol were obtained from 
LKT Laboratories, Inc. (St. Paul, MN). Fluorescein and phenolic standards including 
cyanidin chloride and p-coumaric acid were purchased from Fluka Analytical (Buchs, 
Switzerland). Trolox and rutin were purchased from ACROS (Geel, Belgium). 
Grape Pomace  
Six red wine grape varieties: Chambourcin (hybrid), Merlot (Vitis vinifera), Norton 
(Vitis aestivalis), Petit Verdot (Vitis vinifera), Syrah (Vitis vinifera) and Tinta Cão (Vitis 
vinifera were kindly provided by Chrysalis Vineyards (Middleburg, VA). The pomaces 
were shipped immediately after pressing. Upon receipt of the samples, they were 
immediately dried in a food dehydrator at 95 oF for 28 h. 
Sample Extraction 
The pomaces were separated from stems and ground to a powder consistency 
followed by the manual removal of visible solid impurities. Grape pomace powder was 
soaked and stirred overnight at 450 rpm in aqueous acetone at a concentration of 
0.1g/ml and supernatants were spun at 1,000 rpm for 5 minutes. Supernatants were 
retained and filtered using a 20 µm Whatman filter paper via suction filtration with pump-
generated vacuum. The filtered extract was then transferred to a Buchi Rotavapor 
where the solvent was isolated via evaporation at 50 to 180 RPM and 40 to 60 oC, in 
gradual increments, and condensation at 4-8 oC to obtain a solvent-free grape pomace 
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extract in pure water. The extract was frozen at -80 oC, lyophilized and stored in powder 
form at 4oC for use in screening. The prepared grape pomace extract (GPE) powders 
were reconstituted with aqueous acetone and diluted with ddH2O to a concentration of 
0.5 mg/ml.  
α-Glucosidase Inhibition Screening  
i. Preparation of rat α-Glucosidases  
Intestinal acetone powders from rat were extracted with 0.05 M phosphate buffer 
(PB) pH 6.8 at a concentration of 25 mg/ml. The solution was soaked and stirred 
overnight at 450 RPM and supernatants were isolated and spun at 1,000 rpm for 5 
minutes. Supernatants were retained and filtered via vacuum filtration using a 20 µm 
Whatman filter paper. The filtered solution was frozen at -80oC, lyophilized and 
reconstituted with 0.05 M PB pH 6.8 to a concentration of 25 mg/ml. Ready-to-use 
aliquots of this concentration were stored at -20oC. 
ii. α-Glucosidase Inhibition Assay 
α-Glucosidase enzyme at 25 mg/ml was used from prepared aliquots. 4-
nitrophenyl-α-D-glucopyranoside (pNPG) was used as a substrate at a 4 mM 
concentration. Briefly, α-glucosidase enzyme complex hydrolyzes pNPG and releases 
p-nitrophenol (pNP). Reading the absorbance quantitates the release of pNP thus 
representing enzymatic activity [36]. Acarbose, known to inhibit α-glucosidase enzyme 
complex and used as an oral blood glucose lowering drug in diabetes [57], served as a 
positive control at 50 µg/ml. Enzyme, substrate and positive control solutions were 
prepared in the blank reagent (0.05 M PB pH 6.8) which is in turn used as a negative 
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control. GPE samples, prepared as described above, were screened using this assay. 
Ninety six-well bioassay microplates were prepared to contain 115 µl of sample or 
control, 90 µl of enzyme solution and 45 µl of substrate solution per well, mixed 
thoroughly. Absorbance at a wavelength of 405 nm was obtained at start of the reaction 
using a Perkin Elmer HTS 7000 Bio Assay Reader and software (Perkin Elmer, 
Norwalk, CT). The microplate was then incubated at 37 oC and absorbance reading was 
obtained again at 30 and 90 minutes with intense shaking between cycles. The 
absorbance reading, representing the concentration of pNP, was then used to compare 
the activity of the tested samples: the lower the reading, the less active the enzyme, and 
thus the more active the sample. Percent inhibition by all samples was calculated and 
compared to controls to determine potency, using the following formula: 
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}. 
Antioxidant Assays 
i. Total Phenolic Content (TPC) Assay  
TPC was evaluated with Folin–Ciocalteu’s phenolic reagents. Samples were 
diluted to 2 mg/mL with aqueous acetone. Gallic acid was used as a standard for 
preparing the standard curve. All the samples and standards were run in triplicates. 
Each test tube contained 25 µL of a sample or standard and 250 µL distilled water. 
750 µl Folin-Ciocalteu's phenol reagent was then added to each tube and mixed using a 
vortex mixer. Then, 500 µL of 200 mg/ml sodium carbonate was added to each tube 
and mixed thoroughly. Samples and standards were incubated for 2 h at room 
temperature in the dark. Absorbance was detected at 765 nm and the TPC of each 
sample was expressed as milligrams of gallic acid equivalents (GAE) per mg GPE. 
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ii. DPPH Radical Scavenging Assay 
This assay measures the ability of our samples to quench DPPH radicals. 
Samples were diluted to 5 mg/ml with aqueous acetone and then centrifuged at 6900 
×g for 20 min to eliminate residues [99]. 100 µl of each sample was mixed with 150 µl of 
DPPH  radical solution in a 96-well microplate and absorbance was measured at room 
temperature every 5 min for 2 h at 500 nm. All samples were prepared in triplicates. 
After subtracting sample backgrounds at all time points, the percent scavenging 
capacity was calculated using the following equation:  
Scavenging Effect (%) = {(Absstart – Abstimepoint) /Absstart} × 100. 
iii. Oxygen Radical Absorbing Capacity (ORACFL) Assay 
ORACFL assay was performed as described by Zhou et al with slight 
modifications. Samples were diluted with aqueous acetone to a concentration of 
0.1 mg/ml. Trolox at a concentration gradient served as standard [100]. All samples and 
standards were assayed in triplicates. In each well of a 96-well microplate, 200 µL of 8 
µM fluorescein (in 75 mM PB pH 7.4) was mixed with 40 µL of sample or standard. The 
plate was then shaken and incubated for 15 min at 37 °C and 35 µL of 0.36 M AAPH 
was added to each sample, then fluorescence was measured every 5 min for 90 min at 
an excitation wavelength of 485 nm and an emission wavelength of 520 nm. Results are 
expressed as µmol trolox equivalent (TE)/g dried GPE weight. 
High Performance Liquid Chromatography Analysis 
Fifteen antioxidant compounds, typically reported in grape and wine, were used 
as antioxidant standards to identify and quantify antioxidants in our GPE samples. The 
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extracts were first cleaned using solid phase extraction (Oasis HLB 6 cc extraction 
cartridge, Waters Corporation, Milford, MA) to remove sugar and other contaminants. 
After drying with nitrogen gas, each sample/ standard was dissolved in methanol and 
filtered using a 0.45 micron, 3 mm syringe filter. Reversed-phase HPLC was employed 
to profile individual antioxidants in the cleaned extracts against known phenolic 
standards, using a Hitachi HPLC system (Model L-2455 Diode Array Detector, Model L-
2200 Autosampler, Model L-2100/2130 Pump) from Hitachi High-Tech Technologies 
(Tokyo, Japan). A Phenomenex Aqua 5 µm C18  250 x 4.6 mm analytical column 
(Phenomenex, Torrance, CA) represents the stationary phase while methanol, 0.5% 
acetic acid in 50% acetonitrile and 2% acetic acid were utilized as mobile phase 
solvents A and B, respectively. Twenty µL of each sample was injected via the 
autosampler at a 0-5689 psi pressure range, under room temperature. Gradient 
systems were used as follows: 10–26% A, 0–8 min; 26% A, 8-15 min; 26-30% A, 15–
20 min; 30-55% A, 20–42 min; 55-87% A, 42–75 min; 87-100% A, 75-78 min; 100% A, 
78-83 min; 100-10% A, 83-85 min; 10% A, 85-90 min. Flow rate was set at 1 ml/min. 
Samples and standards were monitored by UV detection and profiled at a wide range of 
wavelengths (200–700 nm), selecting the optimal wavelength for comparison. Profiles of 
standards and samples were compared and antioxidants were detected and quantified 
on the basis of their retention time and UV spectrum. 
α-Glucosidase Inhibition Screening of Antioxidant Standards 
The protocol described earlier was utilized. Antioxidant standards were 
reconstituted in aqueous acetone to a 0.5 mg/ml concentration and screened for α-
glucosidase inhibiting activity.  
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Statistical Analysis 
Results were analyzed via IBM SPSS 22.0 for Windows (IBM Corp., Armonk, 
NY) using one-way analysis of variance (ANOVA). Tukey’s HSD post-hoc analyses 
were employed to compare outcomes using P < 0.05 as a cutoff point for statistical 
significance. Pearson’s correlation was conducted to study the relationship between 
variables. Data for each dependent variable is reported as mean + SEM.  
RESULTS 
Inhibition of Mammalian α-Glucosidases  
Percent enzyme inhibition by GPEs is presented in Fig. 3.1. With the exception of 
Petit Verdot, the selected GPEs showed potent inhibition against rat intestinal α-
glucosidases. At a concentration of 0.5 mg/ml, Tinta Cão exerted the strongest inhibition 
of intestinal α-glucosidases, measured as 95% (P < 0.05). Chambourcin, Norton, Merlot 
and Syrah also exhibited significant activity, ranging from 72% to 88% inhibition. The 
inhibitory effect of these samples surpassed that of Acarbose, a commercial α-
glucosidase inhibitor which exerts ~50% inhibition at 50 µg/ml under the described 
assay conditions. Petit Verdot, on the other hand, demonstrated a poor inhibitory activity 
of 7%.  
Total Phenolic Content (TPC)  
As shown in Fig. 3.2, all the tested pomace samples contained noticeable 
amounts of phenolic compounds at the tested concentration of 2 mg/ml, with the 
exception of Petit Verdot. Merlot GPE contained the highest TPC (0.29 mg GAE/mg) 
followed by Syrah GPE (0.28 mg GAE/mg), Tinta Cão GPE (0.26 mg GAE/mg), 
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Chambourcin GPE (0.19 mg GAE/mg) and Norton GPE (0.14 mg GAE/mg), while Petit 
Verdot GPE contained the least TPC (0.06 mg GPE/mg, P < 0.05).  
DPPH Radical Scavenging 
Antioxidant capacity was evaluated by DPPH radical scavenging assay. Five 
milligrams of the Chambourcin, Merlot and Tinta Cão GPEs quenched 58%, 51% and 
49% of DPPH radicals in the reaction at 120 min, respectively. A lesser yet remarkable 
quenching of the radical was observed with similar concentrations of Syrah (36%) and 
Petit Verdot (34%) GPEs. At the same conditions, Norton GPE scavenged 26% of the 
DPPH radical. All values were significantly higher than the control (P < 0.05), an 
identical reaction containing the sample solvent. Percent DPPH scavenging per tested 
GPE is portrayed in Fig. 3.3.  
Oxygen Radical Absorbance Capacity (ORACFL) 
The ORACFL assay enabled the evaluation of the scavenging capability of the 
selected GPEs against peroxyl radicals (AAPH). As depicted in Fig. 3.4, the six varieties 
appeared to possess a notable oxygen radical scavenging activity at 0.1 mg/ml. Tinta 
Cão GPE exerted the highest ORACFL value, presented as 3204. Closely, Syrah 
quenched the peroxyl radical effectively at 3169 µmol TE/g, followed by Norton, 
Chambourcin and Merlot GPEs which yielded the respective ORACFL values of 2918, 
2878 and 2832 µmol TE/g. Petit Verdot again exhibited lower radical quenching, 
estimated as 1960 µmol TE/g (P < 0.05).  
Correlation 
Table 3.1 summarizes the strong positive correlation that was detected when 
comparing the trends observed in α-glucosidase inhibition, phenolic content, DPPH 
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quenching and AAPH absorbing activity. Using Pearson’s Correlation, the association 
was noted when comparing each two assays. The correlation was significant between 
α-glucosidase inhibition and both TPC and ORAC (P < 0.01), as well as TPC with both 
ORAC and DPPH (P < 0.01 and P < 0.05, respectively). Although DPPH assay results 
did not exhibit a significantly strong correlation with either α-glucosidase inhibition or 
ORAC results, there was a positive correlation.  
Phenolic Acid Composition 
HPLC chromatograms of standards and samples are displayed in Fig. 3.5 and 
Fig. 3.6, respectively. All profiled antioxidants were detected in the 6 GPE samples, in 
varying concentrations. The highest and lowest concentrations of most antioxidants 
were observed in the Chambourcin and Petit Verdot varieties, respectively. The sum of 
concentrations of detected antioxidant compounds was highest by far in Tinta Cão GPE 
(460.6 mg/g), most attributable to the anthocyanin malvidin chloride (439.08 mg/g), and 
lowest in Petit Verdot (11.13 mg/g), with consistently low concentrations of most 
antioxidant compounds, except for caffeic acid (2.10 mg/g), which was most 
concentrated in Petit Verdot GPE among the tested varieties. Sum of concentrations of 
the profiled antioxidants ranged from 23.74 to 145.35 mg/g in the remaining varieties. 
Table 3.2 summarizes the computed data. 
α-Glucosidase Inhibiting Activity of Antioxidant Standards 
α-Glucosidase inhibition screening of the known antioxidants detected in the six 
GPE samples revealed no inhibitory activity. 
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DISCUSSION 
Alpha-glucosidases play a significant role in carbohydrate digestion and 
absorption and therefore postprandial blood glucose, a target for diabetes management 
[82]. The comparison of the α-glucosidase inhibitory potential of several crude grape 
pomace extracts allows the identification of the grape variety that is potentially rich in 
the inhibiting compounds. Although yeast α-glucosidase is readily available in pure form 
and widely used for nutraceutical investigations [101, 102], α-glucosidase from 
mammalian source is more biologically relevant. The mammalian enzyme complex was 
hence extracted and purified from rat intestinal powder. The presented α-glucosidase 
inhibition data is consistent with our previous findings indicating that red wine grapes 
are strong inhibitors of the enzyme [31], with exception to Petit Verdot variety. Having 
obtained the grape pomaces from the same vineyards and followed a consistent sample 
preparation protocol, our findings suggest that Tinta Cão exceeds other tested varieties 
in inhibitory activity due to varietal differences rather than differences in growth and 
preparation conditions. 
The richness of grapes and their pomaces in antioxidants [66-70], and the fact 
that numerous health protective functions have been attributed to antioxidants over the 
last few decades [75, 83, 84], together suggest that a bioactivity exhibited by a grape 
extract may be related to its antioxidant content. A review of literature on plant-derived 
α-glucosidase enzyme inhibitors indicates that known antioxidant compounds such as 
polyphenols, flavonoids and others have exhibited inhibitory activity in vitro [82, 85]. 
This brought about the need to investigate and compare the antioxidant makeup of our 
6 grape varieties. Hence, universal antioxidant assays were employed to quantify the 
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antioxidant content while HPLC profile comparison allowed the detection of major 
differences as well as specific antioxidant compounds.  
According to our results, the tested grape pomace varieties are rich in phenolic 
compounds, with the exception of petit verdot which had the lowest TPC value. Merlot, 
Syrah and Tinta Cão pomace extracts appeared to contain the highest amounts of 
phenolic compounds, with these compounds accounting for 29%, 28% and 27% of the 
dried weight extract of these varieties, respectively. Although higher TPC has been 
previously reported in red grape pomace extracts, like for example Norton (48%, 80% 
ethanol extract) [65] and Bangalore (36%, methanol extract) [71], differences may be 
attributed to source and extraction method/solvent. Interestingly, our observed trend 
appears to go in parallel with our aforementioned α-glucosidase inhibition results. Our 
results hence not only indicate that these three varieties are particularly rich in 
antioxidants, but also hint that the antioxidant content may have contributed to the 
observed enzyme inhibition potency.  
DPPH radical quenching rate of 34-58% suggests that our GPE samples are 
strong free radical scavengers, compared to previously tested grape extracts. For 
instance, ranges of 12.5% to 66.7% have been reported with grape skin extracts [103, 
104]. Amongst our tested varieties, Chambourcin, Merlot and Tinta Cão seem to exhibit 
the strongest antioxidant activity in terms of quenching the DPPH radical, while Norton 
demonstrated the least ability in scavenging the radical.  
The tested GPEs had ORACFL values ranging between 2970 and 4878 µmol 
TE/g dried pomace extract, which is remarkably higher than reported ORACFL values of 
5-92 µmol TE/g fresh weight of common fruits and vegetables [65]. For instance, we 
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have previously estimated the ORACFL value of Norton grape to be 22.9 µmol TE/g 
fresh fruit weight [105]. It hence appears that pomace extracts exert remarkably higher 
peroxyl radical scavenging activity than fresh grapes. When comparing the tested 
varieties in the current study, Tinta Cão appeared to exhibit the highest ORACFL while 
Petit Verdot was at the lower end of the range, in line with their α-glucosidase inhibiting 
capacity and TPC levels.  
When conducting correlation tests to compare the stated trends, we observed a 
positive correlation between all four assays, though not particularly significant between 
all pairs. α-Glucosidase inhibition data correlated strongly with both TPC and ORACFL 
data suggesting that the varieties with a stronger enzyme inhibition capacity also 
exhibited a stronger antioxidant capacity (peroxyl radical scavenging), likely due to their 
richness in phenolic compounds. TPC appeared to be significantly correlated with both 
DPPH and ORAC values. Although several studies correlating TPC and radical 
scavenging results in fruits found that higher TPC does not always correspond to higher 
radical absorbing ability [105, 106], many others have observed a strong positive 
correlation between these parameters [20, 107, 108]. Our data is consistent with the 
studies rendering high antioxidant activity to richness in phenolics [104]. Despite being 
positively correlated with all assays, DPPH results were only significantly correlated with 
TPC. This perhaps may be attributed to the fact that total phenolic content corresponds 
to a total that contains a variety of antioxidants possessing different mechanisms of 
action [109]. Furthermore, the strong α-glucosidase inhibiting activity exhibited by our 
samples may be related to those polyphenols that quench the peroxyl radical, but not 
necessarily the DPPH radical.  
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Finally, inference on individual antioxidants in our samples was obtained via 
HPLC profiling, to detect major differences that may explain the observed trends. The 
anthocyanins cyanidin chloride, delphinidin chloride, malvidin chloride and malvin 
chloride, the flavanols catechin and epicatechin gallate, the flavonols kaempferol, 
myricetin, quercetin hydrate and quercetin 3-o-glucoside, the flavone rutin, the 
hydroxycinnamates caffeic acid and p-coumaric acid, the stilbenoid resveratrol and the 
non-flavonoid phenolic compound gallic acid, have been abundantly reported in grapes, 
particularly red grapes and their extracts and wines [83, 110-112]. They were hence 
selected as standards for antioxidant profiling in the GPE samples. As expected, the 
profiled antioxidant compounds were all detected in the tested samples. Also, the total 
concentration of detected antioxidants was highest with Tinta Cão and lowest with Petit 
Verdot, in line with the aforementioned assay results indicating that the former 
possesses strong antioxidant ability while the latter exhibits the weakest antioxidant 
capacity among the tested varieties. Of interest was the search for antioxidant 
compounds that are particularly deficient in the poor α-glucosidase inhibiting variety, 
Petit Verdot, and antioxidant compounds that are particularly highly concentrated in the 
most potent α-glucosidase inhibiting variety, Tinta Cão. Catechin, p-coumaric acid, 
epicatechin gallate, quercetin 3-o-glucoside, malvidin chloride and resveratrol were 
particularly very low in Petit Verdot GPE. All tested anthocyanins were especially 
concentrated in Chambourcin and Tinta Cao varieties. The concentration of malvidin 
chloride in Tinta Cão was 3.27 times higher than the next most concentrated variety. 
This prompted the evaluation of the α-glucosidase inhibiting capacity of these 
compounds, to identify the compound(s) that may be responsible for the observed 
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differences between the GPE varieties. For this reason, all 15 antioxidant standards 
were screened for α-glucosidase inhibiting activity. To our surprise, none of the 
compounds exhibited this bioactivity, implying that the tested GPEs likely contain an 
unidentified bioactive component that strongly inhibits α-glucosidases and likely exhibits 
antioxidant properties. Of particular concern is the Tinta Cão variety which ranks on the 
top of the list in terms of α-glucosidase inhibition along with antioxidant capacity. 
Conclusion 
Red wine grape extracts, namely Tinta Cão GPE, appear to be novel food-
derived extracts that potently inhibit mammalian α-glucosidases. This reported activity is 
new and likely specific to the grape variety and maybe related to its antioxidant content. 
Although comparing antioxidant activity and content of a sample to those in the 
literature can be difficult at times due to the absence of one universal method and 
reporting fashion, the current results do reveal high antioxidant content/activity that 
strongly correlates with α-glucosidase inhibition. These promising findings may provide 
a foundation for the future development of natural α-glucosidase inhibitors from Tinta 
Cão GPE to potentially use for diabetes management and prevention. Further 
investigation is required to validate and optimize this property.  
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FIGURES 
Fig. 3.1. Percent α-Glucosidase Inhibition per GPE Sample. Enzyme activity was 
determined by measuring p-nitrophenol release from pNPG at 405 nm. Acarbose (50 
µg/ml)  is the standard and denoted as Std. C, Chambourcin. M, Merlot. N, Norton. P, 
Petit Verdot. S, Syrah. T, Tinta Cão. Bars marked with different superscripts are 
significantly different (p<0.05). 
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Fig. 3.2. Total Phenolic Content (TPC) per GPE Sample. TPC was determined using 
Folin-Ciocalteau's reagent. Data is presented as mg gallic acid equivalents (GAE) per 
mg dry GPE weight. C, Chambourcin. M, Merlot. N, Norton. P, Petit Verdot. S, Syrah. T, 
Tinta Cão. Bars marked with different superscripts are significantly different (p<0.05). 
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Fig. 3.3. Percent DPPH Scavenging per GPE Sample. Scavenging capacity was 
measured at 500 nm using 2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl (DPPH) radical. 
The reaction was conducted for 120 min. C, Chambourcin. M, Merlot. N, Norton. P, Petit 
Verdot. S, Syrah. T, Tinta Cão. Control, identical reaction containing the sample solvent. 
Lines marked with different letters are significantly different (p<0.05). 
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Fig. 3.4. Oxygen Radical Absorbance Capacity (ORACFL) per GPE Sample. ORACFL 
was determined using 2,2′-Azobis(2-amidinopropane) dihydrochloride (AAPH) as a 
peroxyl radical generator. Data is presented as µmol Trolox Equivalents (TE) per g dry 
GPE weight. C, Chambourcin. M, Merlot. N, Norton. P, Petit Verdot. S, Syrah. T, Tinta 
Cão. Bars marked with different superscripts are significantly different (p<0.05). 
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Table 3.1. Correlation between α-Glucosidase Inhibition and Antioxidant Capacity. 
Correlation was measured using Pearson’s r. 
NA, not applicable. 
Superscripts denote statistical significance: a p<0.05; b p<0.01 
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Pearson’s Coefficient α-Glucosidase Inhibition TPC DPPH ORAC 
α-Glucosidase 
Inhibition NA 0.882
b
 0.345 0.946b 
TPC 0.882b NA 0.503a 0.802b 
DPPH 0.345 0.503a NA 0.246 
ORAC 0.946b 0.802b 0.246 NA 
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Fig. 3.5. HPLC Chromatogram of the 15 Selected Antioxidant Standards. Standards 
were profiled in triplicate (one shown) to determine the anticipated retention time range 
for each compound. UV spectrum is shown at 280 nm. 1, gallic acid. 2, malvin chloride. 
3, catechin. 4, delphinidin chloride. 5, caffeic acid. 6, cyanidin chloride. 7, p-coumaric 
acid. 8, epicatechin gallate. 9, rutin. 10, quercetin 3-o-glucoside. 11, malvidin chloride. 
12, myricetin. 13, resveratrol. 14, quercetin hydrate. 15, kaempferol. 
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Fig. 3.6. HPLC Chromatograms of the Six Selected GPE Samples. Antioxidant rich 
concentrates isolated by solid phase extraction were profiled. Each sample is a complex 
mixture of compounds, including the profiled antioxidants. Peak numbers represent 
detected antioxidant standards. Spectra are displayed at 280 nm. 
(a) Chambourcin. (b) Merlot. (c) Norton. (d) Petit Verdot. (e) Syrah. (f) Tinta Cão. 
  
  
 
 
 
 
 
  
(b) Merlot 
(a) Chambourcin 
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(d) Petit Verdot 
(c) Norton 
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(f) Tinta Cão 
(e) Syrah 
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Table 3.2. Concentrations of the Detected Antioxidants in the GPE Samples. Following 
antioxidant detection based on retention time (RT), concentration was determined by 
measuring and comparing peak area of each detected compound in the sample and the 
standard chromatogram. Data is presented as milligrams of detected antioxidant per 
gram of crude GPE, and numbers in green and red represent highest and lowest 
concentration per row, respectively. C, Chambourcin. M, Merlot. N, Norton. P, Petit 
Verdot. S, Syrah. T, Tinta Cão. 
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Peak Antioxidant Assignment 
RT Range 
(minutes) 
GPE Samples (mg/g crude extract) 
C M N P S T 
1 Gallic acid 6.2-6.5 2.83 0.82 0.44 0.55 0.93 1.27 
2 Malvin chloride 11.9-12.3 3.44 0.34 0.67 0.23 0.36 1.18 
3 Catechin 14.4-15.1 7.38 1.70 1.05 0.12 4.31 3.78 
4 Delphinidin chloride 17.2-17.8 0.85 0.70 0.52 0.41 0.76 4.95 
5 Caffeic acid 18.2-19.2 1.51 0.48 0.74 2.10 1.14 0.86 
6 Cyanidin chloride 24.3-26.2 1.24 0.30 0.45 0.17 0.25 0.45 
7 p-Coumaric acid 27.9-29.2 0.42 0.13 0.13 0.03 0.12 0.21 
8 Epicatechin gallate 32.2-33.5 1.16 0.26 0.38 0.02 0.43 0.44 
9 Rutin 32.9-33.8 2.55 0.39 1.11 1.27 0.91 2.57 
10 Quercetin 3-o-glucoside 34.5-35.5 4.05 0.37 1.59 0.05 0.72 3.29 
11 Malvidin chloride 40.9-41.6 37.65 17.93 15.38 4.57 134.14 439.08 
12 Myricetin 42.9-44.1 0.86 0.31 0.48 0.18 0.30 0.47 
13 Resveratrol 46.1-47.3 0.65 0.21 0.27 0.08 0.38 0.88 
14 Quercetin hydrate 52.9-54.0 1.26 1.10 0.29 1.18 0.33 0.84 
15 Kaempferol 62.9-64.1 0.21 0.24 0.23 0.17 0.27 0.33 
 Total  66.06 25.27 23.74 11.13 145.35 460.60 
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Abstract 
Alpha-glucosidases play a major role in controlling starch digestion and therefore 
postprandial blood glucose, a target for diabetes management. This study aims to 
prepare and purify active components in Tinta Cão grape pomace extract (GPE) that 
inhibit intestinal α-glucosidases. Tinta Cão GPE, previously shown to potently inhibit the 
enzyme, was partitioned into water, butanol and ethyl acetate extracts which were 
evaluated for rat intestinal α-glucosidase (25 mg/ml) inhibiting activity. The active extract 
was fractionated via several open column chromatography techniques and the retained 
fractions were tested.  The most active fraction was further separated via HPLC and the 
collected fractions were evaluated. The active compound was then identified using NMR 
and MS analysis. At 0.5 mg/ml, the ethyl acetate fraction was the most effective inhibitor 
of α-glucosidase (68.14% inhibition, compared to 16.28-53.4%). Aqueous ethanol-
eluted fractions of the HP-20 column outweighed the standard (Acarbose 50 µg/ml, 50% 
inhibition) at 69.82% inhibition. HPLC purification yielded an active compound that was 
later determined to be D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}. 
Results were significant, suggesting that a potent inhibitor of intestinal α-glucosidases 
can be isolated from Tinta Cão grapes for the potential development of a novel anti-
hyperglycemic dietary supplement.  
 
Key words: Grape Pomace; Tinta Cão; α-Glucosidase; Diabetes 
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Introduction 
The prevalence of diabetes has become overwhelming. Diabetes currently 
affects 8.3% of the U.S. population [18], a number that is projected to double or triple by 
2050 [19]. This epidemic has become a massive health burden significantly decreasing 
quality of life and increasing morbidity and mortality among Americans, all at a huge 
economic cost [21].  
 This alarming global rise in diabetes rates has made it necessary to explore 
novel approaches to prevent and control the disease. Traditional anti-hyperglycemic 
agents have shown limited long-term efficacy and often come with considerable side 
effects [31]. The huge economic costs, inability to provide durable glycemic control as 
well as the development of side effects ranging from hypoglycemia to impaired 
gastrointestinal function have raised concerns regarding the use of common anti-
hyperglycemic agents, namely metformin, sulfonylureas, thiazolidinediones, GLP-1 
receptor agonists, and even insulin [25, 29, 30, 32-35]. Therefore, it is crucial to develop 
alternative therapeutic strategies that will broaden treatment options and provide a safe 
and affordable substitute to currently available therapies.  
 In the shift from the traditional management of blood glucose, treatment of 
postprandial hyperglycemia has become an intriguing target to improve overall glycemic 
control [36-40]. Postprandial hyperglycemia, one of the earliest signs of type-2 diabetes, 
is thought to aggravate the disease by inducing glucose toxicity and ß-cell function 
deterioration which can ultimately give rise to an irreversible state of diabetes [39, 41]. 
Since it is linked to the amount of consumed starch and its rate of digestion [36], 
postprandial hyperglycemia can be managed by controlling carbohydrate digestion and 
absorption [44-46], specifically by inhibiting digestive enzymes responsible for the 
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break-down of starch [46-50]. For instance, the inhibition of α-glucosidases is effective 
in both preventing and treating type-2 diabetes through reducing postprandial 
hyperglycemia [52]. However, available inhibitors that have been used for diabetes 
treatment (i.e. Acarbose) were found to exhibit a non-specific inhibition of α-amylase, 
resulting in excessive accumulation of undigested carbohydrate in the colon, thus 
generating undesirable gastrointestinal side effects [36]. Research aiming at identifying 
novel inhibitors has increased in the last three decades. We have recently found several 
antioxidant rich red grape pomace extracts (GPEs), namely the Tinta Cão variety, to 
possess an impressive α-glucosidase inhibiting property (Chapter 3). The components 
responsible for this activity are unknown, to our knowledge. 
 The current research aims to isolate and identify the component(s) in Tinta Cão 
GPE responsible for its observed α-glucosidase inhibiting activity. The results may pave 
the way for the future development of a natural α-glucosidase inhibitor from red wine 
grapes, thus establishing a novel anti-diabetic strategy. 
MATERIALS AND METHODS 
Materials 
HPLC grade organic solvents were utilized for grape pomace extraction, column 
chromatography and HPLC analysis (Fisher Scientific, Atlanta, GA). Intestinal acetone 
powders from rat and 4-nitrophenyl-α-D-glucopyranoside (pNPG) were purchased from 
Sigma-Aldrich (St. Louis, MO). Acarbose was obtained from LKT Laboratories, Inc. (St. 
Paul, MN). HP-20 Diaion Resin Styrenic Adsorbent was purchased from Sorbent 
Technologies (Atlanta, GA).  
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Grape Pomace Extract Preparation 
Grape pomace extraction procedure described in Chapter 3 was followed. Tinta 
Cão (Vitis vinifera) grape pomace was kindly provided by Chrysalis Vineyards 
(Middleburg, VA) via the Agricultural Research Station at Virginia State University 
(Petersburg, VA). Briefly, Fresh pomace was dried in a food dehydrator at 95 oF for 28 h 
then ground to a powder consistency. Grape pomace powder was soaked and stirred 
overnight in aqueous acetone and supernatants were spun then filtered via suction 
filtration. The solvent was then isolated from the extract via evaporation and 
condensation. The water extract was lyophilized to then be reconstituted with aqueous 
acetone. 
Bioactivity-Driven Fractionation of GPE 
i. Liquid-Liquid Partition 
A batch-wise single stage extraction method was followed. The water-GPE 
solution of aqueous acetone grape extraction was mixed with an equal volume of ethyl 
acetate in a separating funnel. The solution was exposed to repetitive intervals of 
vigorous shaking and rest until two distinct layers were observed. The isolated aqueous 
phase was exposed to another round of batch-wise single stage extraction with butanol. 
The ethyl acetate and butanol fractions were air-dried overnight and the water fraction 
was dried via rota-evaporation and sublimation. Powder fractions obtained were stored 
at 4 oC for future use. 
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ii. Column Chromatography Separation 
Open glass columns were packed with silica gel (normal phase), diaion HP-20 
(reversed-phase), C18 (reversed-phase), Sephadex LH-20 (molecular sizing), Cyano 
sorbent (universal phase) and Dowex resin (ion exchange). These stationary phases 
were examined for their capacity for separation with acetone, methanol, ethyl acetate 
and methylene chloride being used as eluents. The method yielding sub-fraction(s) with 
highest enzyme inhibition potency and potential for reproducibility was selected as the 
optimal fractionation method. After extensive evaluation and comparison, HP-20 open 
column was selected, using HP-20 Diaion Resin Styrene-Divinylbenzene Adsorbent, a 
polyaromatic adsorbent. Resin properties were as follows: 260 Å porosity, 250-850 µm 
particle size, 600 m2/g surface area, 680 g/L bulk density, and 55-65% water content. 
The column used was a Synthware 45/50 ST joint, 2.7 x 22 in column (VWR 
International, Radnor, PA). Eluents were 100% H2O, 30% ethanol, 50% ethanol, 70% 
ethanol, and 100% ethanol. Thin layer chromatography (TLC) and HPLC were then 
used to determine the point in the separation process when a single pure active 
compound has been isolated. 
iii. High Performance Liquid Chromatography (HPLC) Purification 
HPLC method previously utilized (Chapter 3) was employed with slight 
modifications. The rotaevaporation-dried GPE sub-fractions were dissolved in methanol 
and filtered using a 0.45 micron, 3 mm syringe filter. Reversed-phase HPLC was 
employed to study purity and separate compounds, using a Hitachi HPLC system from 
Hitachi High-Tech Technologies (Tokyo, Japan). A Macherey-Nagel Phenomenex 5 µm 
C18  250 x 10 mm analytical column (Macherey-Nagel Inc., Bethlehem, PA) represents 
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the stationary phase while methanol and H2O were utilized as mobile phase solvents A 
and B, respectively. Twenty µL of a sub-fraction was injected via the autosampler at a 0-
5689 psi pressure range, under room temperature. Gradient systems were used as 
follows: 0–35% A, 0–3 min; 35% A, 3-10 min; 35-53% A, 10–13 min; 53% A, 13–16 min; 
53-100% A, 16–20 min; 100% A, 20-22 min; 100-35% A, 22-25 min; 35% A, 25-28 min. 
Flow rate was set at 2.5 ml/min. Samples were monitored by UV detection (220-310 
nm) thus determining whether each sample is a pure compound or a complex mixture. 
Complex mixtures were separated, and retained compounds/ simple fractions of the 
injected sample were collected in a Foxy Jr. Fraction Collector (Teledyne Isco, Lincoln, 
NE). 
Chemical Structure Elucidation  
NMR in combination with MS was performed in the Chemistry Department at 
Wayne State University to elucidate the structure of the isolated active compound(s). 
The compounds were analyzed on a Waters LCT Premier high resolution exact mass 
spectrometer (Waters Corp., Milford, Massachusetts).  NMR spectra (1H, 13C, DEPT) 
was generated using a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto, 
California). Through analysis of chromatograms and spectra, and comparison with data 
previously reported in the literature, the chemical structure of the compound(s) was 
determined. 
α-Glucosidase Inhibition Screening  
As previously described (Chapter 3), Intestinal acetone powders from rat were 
extracted with 0.05 M phosphate buffer (PB) pH 6.8, and retained α-glucosidase 
enzyme extract was reconstituted with the same buffer to a concentration of 25 mg/ml. 
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Four mM 4-nitrophenyl-α-D-glucopyranoside (pNPG) was used as a substrate while 50 
µg/ml Acarbose served as a positive control. Ninety six-well bioassay microplates were 
prepared to contain 115 µl of GPE fraction/ sub-fraction or control, 90 µl of enzyme 
solution and 45 µl of substrate solution per well. Absorbance was obtained at a 405 nm 
wavelength at the start of the reaction and following a 30 min incubation at 37 oC, using 
a Perkin Elmer HTS 7000 Bio Assay Reader and software (Perkin Elmer, Norwalk, CT). 
Percent inhibition by tested samples was calculated using the following formula: 
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}. 
Statistical Analysis 
Results were analyzed using one-way analysis of variance (ANOVA) and Tukey’s 
HSD post-hoc analyses, comparing outcomes with P < 0.05 indicating statistical 
significance. SPSS 22.0 for Windows (IBM Corp., Armonk, NY) was utilized to perform 
these tests. Data for each dependent variable is reported as mean + SEM.  
RESULTS 
Inhibition of Mammalian α-Glucosidases  
i. Activity of GPE Fractions 
Two of the Tinta Cão GPE fractions significantly suppressed rat intestinal α-glucosidase 
enzyme activity. Percent enzyme inhibition by GPE fraction is presented in Fig. 4.1. At a 
concentration of 0.5 mg/ml, the ethyl acetate-soluble fraction of Tinta Cão GPE exerted 
the strongest inhibition of intestinal α-glucosidases, measured as 68.14% (P < 0.05). 
The water-soluble fraction exhibited a lesser yet remarkable inhibitory effect (53.4%), 
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comparable to the effect of the standard Acarbose, a commercial α-glucosidase inhibitor 
which exerts ~50% inhibition at 50 µg/ml under the described assay conditions.  
ii. Activity of GPE Sub-Fractions 
Following TLC-assisted elimination of redundant EA-GPE-derived sub-fractions, 
it was determined that 5 sub-fractions (at 0.5 mg/ml) outweighed the standard in 
enzyme inhibition. Fraction 2 of the HP-20 open column, eluted with 30% (v/v) ethanol, 
exhibited 69.82% inhibition. It was selected for further fractionation since it was 
significantly more active than all tested sub-fractions and the standard (P < 0.05), and it 
appeared more reproducible than the others. Furthermore, HPLC analysis revealed that 
this fraction is a mixture of a small number of compounds. Activity of sub-fractions is 
summarized in Fig. 4.2.  
iii. Activity of GPE-Derived Pure Compounds 
HP-20 fraction 2 underwent HPLC purification yielding four HPLC fractions, as 
shown in Fig. 4.3. Fractions 1, 2 and 3 consisted of single compounds, whereas fraction 
4 was likely not a single compound. As portrayed in Fig. 4.4, upon α-glucosidase 
inhibition screening, it appeared that compounds 1 and 2 possessed the inhibitory 
activity under question, with 67.73% and 75.34% inhibition, respectively. On the other 
hand, no remarkable activity was observed with fractions 3 and 4. Compounds 1 and 2 
were hence selected for chemical characterization.   
Identification of Active Compound 
Upon NMR and MS analysis, it appeared that compounds 1 and 2 are identical. 
They are conformational isomers of the same compound. The NMR and MS spectra of 
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the isolated active compound, shown to exhibit a strong α-glucosidase inhibition, are 
presented in Fig. 4.5. The structure, which was later elucidated, is presented in Fig. 4.6. 
The compound was determined to be: D-Glucopyranose 6-{(2E)-3-(4-
Hydroxyphenyl)prop-2-enoate}, a phenyl glycoside. A review of the literature determines 
that it was reported once by Huang et al., isolated from Picrorhiza scrophulariiflora 
[113]. The compound is a yellowish powder, soluble in water, phosphate buffers and 
universal organic solvents. One Kg of dry Tinta Cão grape pomace yielded 7.65 mg of 
the active compound, following the above-mentioned fractionation and purification 
methods. 
DISCUSSION 
Research investigating the biological activity of plant-derived components 
commonly requires the isolation and characterization of bioactive compounds prior to 
proceeding to further evaluation [91, 114, 115]. A crude plant extract is a complex 
combination of bioactive compounds and phytochemicals, out of which only one or a 
few are responsible for the functional property of interest. Separation hence poses a 
challenge, usually involving various steps and multiple fractionation techniques [91]. 
Liquid-liquid extraction is a helpful initial step to break down the crude extract into parts 
with different properties, based on components’ relative solubility in two 
different immiscible liquids  [92]. The active components of interest in our search for α-
glucosidase inhibiting components in Tinta Cão GPE were mostly concentrated in the 
ethyl acetate-soluble fraction. Column chromatography, a popular fractionation method 
[93], was then employed to further fractionate the ethyl acetate-soluble fraction of Tinta 
Cão GPE, followed by HPLC for further purification and analysis. The latter yielded four 
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simplified fractions of which three were determined to be pure compounds according to 
UV spectra. However, they were not identified as known compounds. Bioassay was 
again required to determine the activity of the generated samples and select the 
bioactive entity, and it suggested that two of the isolated compounds are strong 
inhibitors of α-glucosidase. 
The determination of the chemical structure and formula of the isolated compound was 
then achieved via combinatorial chemistry. Confirmation usually relies on verification of 
information by comparison of liquid chromatography-mass spectrometry (LC-MS) and 
nuclear magnetic resonance (NMR) data. Utilizing these techniques along with 
reviewing the literature indicated that the active compounds were actually 
conformational isomers of the same compound and determined this compound to be D-
Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, a phenyl glycoside 
previously characterized by Huang et al [113]. The review of the literature also indicates 
that this compound has not been previously investigated for bioactivity, particularly α-
glucosidase inhibition and antioxidant capacity. A natural, food-derived compound 
possessing the potential for the development of an anti-hyperglycemic supplement is a 
very promising future anti-diabetic strategy. 
Conclusion 
Tinta Cão grape is a biomass that possesses a remarkable ability to inhibit 
mammalian α-glucosidases. This property appears to be derived from at least one 
compound, D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, isolated from 
the pomace of this grape variety (Fig. 4.7). These findings are new and carry promising 
potential for the future development of a novel food-derived natural supplement for 
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diabetes management and prevention. Further assessing the safety and applicability of 
this compound will aid in determining the future directions.  
FIGURES 
Fig. 4.1. Percent α-Glucosidase Inhibition per GPE Fraction. Enzyme activity was 
determined by measuring p-nitrophenol release from pNPG at 405 nm. Acarbose (50 
µg/ml) is the standard and denoted as Std. H2O, water fraction. EA, ethyl acetate 
fraction. BuOH, butanol fraction. Bars marked with different superscripts are significantly 
different (p<0.05). 
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Fig. 4.2. Percent α-Glucosidase Inhibition per GPE Sub-Fraction. Enzyme activity was 
determined by measuring p-nitrophenol release from pNPG at 405 nm. Acarbose (50 
µg/ml) is the standard and denoted as Std. C18, reverse phase C18 column. HP20, 
diaion resin HP-20 column. SPE, solid phase extraction. S1, silica gel column 1. S2, 
silica gel column 2. Bars marked with different superscripts are significantly different 
(p<0.05). 
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Fig. 4.3. HPLC Chromatogram of GPE-Derived Active Sub-Fraction. S, solvent peak. 1, 
fraction 1, single compound. 2, fraction 2, single compound. 3, fraction 3, single 
compound. 4, fraction 4, likely not a single compound. 
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Fig. 4.4. α-Glucosidase Inhibitory Activity of GPE-Derived HPLC Fractions. Enzyme 
activity was determined by measuring p-nitrophenol release from pNPG at 405 nm. 
Acarbose (50 µg/ml) is the standard and denoted as Std. 1, compound 1. 2, compound 
2. 3, compound 3. 4, HPLC fraction 4. Bars marked with different superscripts are 
significantly different (p<0.05). 
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Fig. 4.5. NMR and MS Spectra of the Isolated Active Compound.  
(a) H-NMR spectrum. (b) C-NMR spectrum. (c) MS spectrum. 
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Fig. 4.6. Chemical Structure of the Isolated Active Compound. The compound was 
determined to be: D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}. 
Conformational isomer 1: R1=H, R2=OH. Conformational isomer 2: R1=OH, R2=H. 
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Fig. 4.7. Summary of the Active Compound Isolation Steps. Enzyme inhibition assay 
followed each step. Tinta Cão grape pomace extract was subjected to liquid-liquid 
partition yielding 3 fractions, of which the ethyl-acetate soluble fraction was determined 
to be the strongest α-glucosidase inhibitor. This fraction was further fractionated via 
multiple column chromatography techniques yielding numerous sub-fractions, of which 
fraction 2 of the HP-20 column was the most potent sub-fraction. This sub-fraction was 
purified via HPLC resulting in an active pure compound that was elucidated with NMR 
and MS and found to be consistent with D-Glucopyranose 6-{(2E)-3-(4-
Hydroxyphenyl)prop-2-enoate} 
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CHAPTER 5 
The Applicability of Grape Pomace-Derived D-Glucopyranose6-{(2E)R-3-(4-
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Abstract 
This study was designed to evaluate the applicability of grape pomace-derived D-
Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate} as a natural inhibitor of α-
glucosidases. This compound was isolated from a Tinta Cão grape pomace extract 
previously shown to be a potent inhibitor of the enzyme complex. In the current study, 
the compound’s dose response in inhibiting α-glucosidases was evaluated and 
specificity examination followed. Then, antioxidant activity of the compound was 
evaluated by free radical assays. Thermal, pH and shelf-life stability of the active sub-
fraction/compound was then tested after exposing it to a range of temperature, pH and 
storage conditions. Lastly, cytotoxicity of the compound was determined through MTS 
assay utilizing NIH/3T3 cells. The isolated compound inhibits α-glucosidase and not α-
amylase. Furthermore, it is a dose-dependent inhibition, exerted by predominantly 
inhibiting the maltase and isomaltase moieties of α-glucosidase. The compound also 
possesses an impressive antioxidant capacity. In terms of stability, it was shown to 
withstand temperature and pH extremes but lose activity upon prolonged storage and 
prolonged exposure to light. Lastly, at 25 and 50 µg/ml, the active compound was not 
cytotoxic to cells (90% cell viability). It was concluded that the compound, besides being 
a potent α-glucosidase inhibitor, is a strong antioxidant that is fairly stable under 
different environmental conditions and likely safe for human consumption. These results 
suggest that D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, isolated 
from Tinta Cão grape pomace is a promising agent for the potential development of an 
anti-hyperglycemic dietary supplement, following pre-clinical and clinical testing.  
Key words: Grape Pomace; α-Glucosidase; Diabetes; Specificity; Stability; Safety 
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Introduction 
Diabetes rates are on a continuous dramatic increase worldwide, a trend that is 
anticipated to continue over the next two decades [116]. While this epidemic is 
uncontrollably spreading, currently available treatment options are often limited by 
suboptimal efficacy and side effects [30, 31]. This brings about the need to develop new 
approaches to prevent and control diabetes. Treatment of postprandial hyperglycemia, 
a promising therapeutic target for improving overall glycemic control [36, 37, 39], can be 
achieved by controlling carbohydrate digestion and absorption [44-46]. For instance, 
reduction of postprandial hyperglycemia through α-glucosidase inhibition has been 
effective in both preventing and treating type-2 diabetes [38, 52, 55]. Nonetheless, 
commercial inhibitors (i.e. Acarbose) were found to exhibit a non-specific inhibition of α-
amylase due to similarities in the target enzymes, resulting in excessive accumulation of 
undigested carbohydrate in the colon, which in turn gives rise to gastrointestinal side 
effects [36, 56, 57].  
We have observed a potent α-glucosidase inhibition exhibited by a Tinta Cão 
grape pomace- derived compound (Chapter 4); however, the specificity of this 
compound has not been determined. Another measure of specificity to be considered 
with mammalian intestinal α-glucosidase enzyme complex is the enzyme moiety 
responsible for the observed effect, as the complex consists of three enzymes: sucrase, 
maltase and isomaltase, responsible for the digestion of sucrose, maltose and 
isomaltose, respectively [96]. Once specificity is determined, the mechanism of action of 
the agent of interest can be identified. Dose response information is essential in drug 
development as it provides the necessary effectiveness and safety guidelines 
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associated with dosing [117]. Testing the likelihood of dose dependence in vitro can 
provide valuable information to be applied in preclinical and clinical studies.  
Instability is a common problem in natural medicines. Stability tests to ensure 
product quality, safety, and efficacy are required prior to the approval of any 
pharmaceutical product [118]. Intermediate length testing should cover a minimum of six 
months duration, however, it is considered unnecessary to continue testing if a 
significant change in efficacy is seen in the first three months [119]. A loss of activity up 
to 85% can lead to failure in therapy, and is considered a significant loss of activity 
[118]. Another necessary safety measure is cytotoxicity studies. An isolated active 
compound requires testing to ensure it is safe in pure form. The edibility of a plant is no 
guarantee that its individual constituents are safe to consume, and vice versa. Plant 
research is currently separated into ethnopharmacology (ex. medicinal herbs) and 
toxicology (ex. poisonous plants), both leading to the production of drugs and lead 
compounds [120].   
Lastly, the phenolic nature of the isolated compound, as shown in Chapter 4, in 
addition to the antioxidant and enzyme inhibition correlation observed in Chapter 3, 
prompt the investigation of the antioxidant capacity of this compound. Plant-derived 
phenolics are well known for their bioactive properties [121]. Particularly, these 
compounds have exemplary antioxidant functions [122].  
The current research aims to assess the safety and applicability of the isolated 
compound by characterizing its inhibition mode and determining its stability and 
cytotoxicity. It also aims to understand the observed correlation between α-glucosidase 
inhibition and antioxidant capacity, noted in Chapter 3. This research may provide the 
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groundwork for the future development of a specific, food-derived α-glucosidase 
inhibitor from grape pomace for preventing and treating diabetes, thus establishing a 
novel, safe dietary anti-diabetic strategy. 
MATERIALS AND METHODS 
Materials 
Intestinal acetone powders from rat, 4-nitrophenyl-α-D-glucopyranoside (pNPG), 
α-amylase from porcine pancreas type VI-B, 3,5-dinitrosalicylic acid (DNS), 2,2-Di(4-
tert-octylphenyl)-1-picrylhydrazyl (DPPH) and Dulbecco’s Modified Eagle’s Medium 
(DMEM) were purchased from Sigma-Aldrich (St. Louis, MO). Autokit Glucose CII and 
2,2′-Azobis(2-amidinopropane) dihydrochloride (AAPH) were acquired from Wako 
Chemicals USA, Inc. (Richmond, VA). Maltose, sucrose and potato starch were 
purchased from Fisher Scientific (Pittsburgh, PA). Isomaltose was purchased from TCI 
America (Portland, OR). Acarbose was obtained from LKT Laboratories, Inc. (St. Paul, 
MN). Mouse embryonic fibroblast (MEF) cell line, NIH/3T3 (CRL-1658) was obtained 
from ATCC (Manassas, VA). CellTiter 96 AQueous One Solution Reagent was obtained 
from Promega (Madison, WI). Fluorescein was purchased from Fluka Analytical (Buchs, 
Switzerland), and Trolox was purchased from ACROS (Geel, Belgium).  
α-Glucosidase Inhibition Screening  
Enzyme extraction and inhibition screening methods previously described 
(Chapters 3 and 4) were followed. Briefly, intestinal acetone powders from rat were 
extracted with 0.05 M phosphate buffer (PB) pH 6.8, and retained, lyophilized α-
glucosidase enzyme extract was reconstituted with the same buffer to a concentration 
of 25 mg/ml. Four mM 4-nitrophenyl-α-D-glucopyranoside (pNPG) was used as a 
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substrate while 50 µg/ml Acarbose served as a positive control. Ninety six-well bioassay 
microplates were prepared to contain 115 µl of sample, 90 µl of enzyme solution and 45 
µl of substrate solution per well. Absorbance was obtained at a 405 nm wavelength at 
the start of the reaction and following a 30 min incubation at 37 oC, using a Perkin Elmer 
HTS 7000 Bio Assay Reader and software (Perkin Elmer, Norwalk, CT). Percent 
inhibition by tested samples was calculated using the following formula: 
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}. 
Mechanism of Action Tests 
i. Dose Response Test 
To understand whether the observed rat α-glucosidase inhibitory effect is dose-
dependent, the previously described enzymatic assay was performed with multiple 
concentrations of the sample (0.1, 0.25 and 0.5 mg/ml) and percent inhibition trend in 
response to concentration change was calculated. 
ii. Enzyme Specificity  
ii.a. Pancreatic α-Amylase Inhibition Assay 
Pancreatic α-amylase inhibition assay followed, using the protocol described by 
Zhang et al [36] with modifications. Briefly, 50 µl of the active compound (0.5 mg/ml, 
aqueous acetone) was incubated with 50 µl enzyme solution (0.17 mg/ml, ddH2O) for 5 
min at room temperature. Following preincubation, 100 µl substrate solution (0.5% 
potato starch, 20 mM PB pH 6.9) was added to the solution and the cocktail was 
incubated for 3 min at 37oC. The reaction was stopped by adding 100 µl color reagent 
(DNS) and incubating for 10-15 min at 85-90 oC. After heating, the assay cocktail was 
allowed to cool for 10 min at room temperature. Fifty µl of the cocktail was then loaded 
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into a well containing 175 µl ddH2O, in a 96-well assay plate. The assay was conducted 
in triplicate and absorbance, representing maltose release, was measured at 540 nm 
using a Perkin Elmer HTS 7000 Bio Assay Reader. The result was compared to that of 
control, prepared with sample solvent instead of sample. Percent enzyme inhibition was 
calculated using the following formula: 
% Inhibition = 100 – {(Abssample/ Abscontrol) x 100}. 
ii.b. Single α-Glucosidase Enzyme Inhibition Assay 
The activity of the active compound against α-glucosidase was estimated utilizing 
the active sub-fraction from which it was extracted, with different substrates to identify 
specificity. The sub-fraction was reconstituted in aqueous acetone and diluted to 5 
mg/ml. The sample was tested using the α-glucosidase enzyme inhibition assay 
described earlier, coupled with a Mutarotase-GOD Glucose assay. The previously 
described assay cocktail was prepared excluding pNPG. Instead, maltose (0.125 M), 
sucrose (0.5 M) and isomaltose (0.125 M) served as enzyme substrates in three 
separate assays. Glucose production in each assay represented enzymatic activity. 
Glucose was detected via an Autokit Glucose CII following the manufacturer’s protocol. 
Results of the three assays were compared thus identifying the target enzyme in the 
multi-enzyme complex. 
Antioxidant Evaluation of Active Compound 
i. DPPH Radical Scavenging Assay 
The protocol followed by Brand-Williams et al was modified [99]. The isolated 
active compound was tested at 0.5, 1 and 5 mg/ml (in aqueous acetone) for its ability to 
quench DPPH. 100 µl of sample was mixed with 150 µl of DPPH  radical solution in a 
89 
 
 
96-well microplate and absorbance was measured at room temperature every 5 min for 
2 h at 500 nm. Variants were prepared in triplicates. After subtracting sample 
backgrounds at all time points, the percent scavenging capacity was calculated using 
the following equation:  
Scavenging Effect (%) = {(Absstart – Abstimepoint) /Absstart} × 100. 
ii. Oxygen Radical Absorbing Capacity (ORACFL) Assay 
ORACFL assay described by Zhou et al [100] was performed with slight 
modifications. Active compound was diluted with aqueous acetone to 40 and 200 µM. 
Trolox which served as standard was prepared in concentrations of 0, 20, 40, 80, 100 
and 200 µM in aqueous acetone. Sample variants and standards were assayed in 
triplicates. In each well of a 96-well microplate, 200 µL of 8 µM fluorescein (in 75 mM 
PB pH 7.4) was mixed with 40 µL of sample or standard. The plate was then incubated 
for 15 min at 37 °C followed by the addition of 35 µL of 0.36 M AAPH to each well, then 
fluorescence was measured every 5 min for 90 min at an excitation wavelength of 
485 nm and an emission wavelength of 520 nm. Results are expressed as antioxidant 
power in relative fluorescence units (RFU). 
iii. ABTS Radical Cation Decolorization Assay 
The protocol described by Re et al [123] was modified. 2,2′-azinobis(3-
ethylbenzothiazoline -6-sulfonic acid) (ABTS) was oxidized into a reactive cation by the 
addition of potassium persulfate to a concentration of 7 mM ABTS/ 2.5 mM potassium 
persulfate, and the cation solution was incubated in the dark at room temperature for 12 
hours. After preincubation, the solution was diluted 70-fold. Then, 200 µl of the cation 
solution was mixed in a well of a 96-well plate with 10 µl of control (sample solvent), 
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standard (200 µM trolox) or sample (200 and 400 µM active compound). Absorbance, 
representing radical cation neutralization by standard/sample, was measured at 405 nm 
after 5 minutes of incubation at room temperature. Readings were recorded every 
minute for 31 minutes. Percent neutralization at each time point was calculated using 
the following formula: 
% Neutralization = 100 – {(Abssample/ Abscontrol) x 100}. 
Stability Tests 
i. Thermal Stability  
The active sub-fraction (reconstituted in water) was heated to 50ºC, 80ºC, 100ºC, 
and 121ºC for 15 minutes using a Fisher Scientific Isotemp hot plate. Samples were 
removed to ice for 10 minutes for immediate cooling. Following heat treatment, the level 
of bioactivity of the samples at 1 mg/ml was assessed via α-glucosidase enzyme 
inhibition assay as previously described. Untreated sample was included as control.  
ii. pH Stability  
Buffers were prepared at pH 3, 4, 5, 6, 7, 8, 9, and 10. Solutions of the active 
sub-fraction were incubated in buffer for 4 hours. The level of bioactivity of the sub-
fraction at different pH levels was assessed at 0.5 mg/ml via α-glucosidase enzyme 
inhibition assay as previously described. Buffers at each pH value were included in this 
assay as controls.   
iii. Shelf-Life and Storage 
The activity of the isolated active compound following storage in various 
conditions was evaluated. The conditions chosen for this test were: -20ºC freezer, 3-4ºC 
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fridge, room temperature (dark), and room temperature (light). They were tested for a 
period of 8 months, or until a significant loss of activity was exhibited.  
MTS Assay for Cytotoxicity 
The compound’s cytotoxicity was determined by MTS assay using mouse 
embryonic fibroblast (MEF) cell line, NIH/3T3. MTS assay was conducted as described 
by Ji et al with slight modifications [124]. The active compound was dissolved in 
methanol to prepare a stock solution with a concentration of 1 mg/ml. Then, serial 
dilutions with DMEM were performed to make working solutions of 25 µg/ml and 50 
µg/ml, in 2.5% and 5% methanol, respectively. The NIH/3T3 cells (5 x 103) were seeded 
in a 96-well culture plate and after overnight incubation, the medium was removed and 
replaced with a fresh medium containing methanol (solvent control, 2.5% or 5%) or 
active compound (25 or 50 µg/ml). After 72 h of incubation, 15 µl of CellTiter 96 AQueous 
One Solution Reagent was added to each well. After 2 h incubation at 37 °C in a 
humidified, 5 % CO2 atmosphere, absorbance was recorded at 485 nm on a Perkin 
Elmer HTS 7000. Each variant of the experiment was performed in octuplicate.  
Statistical Analysis 
Results were analyzed via IBM SPSS 22.0 for Windows (IBM Corp., Armonk, 
NY) using Student’s t-test and one-way analysis of variance (ANOVA). Tukey’s HSD 
post-hoc analyses were employed to compare outcomes using P < 0.05 as a cutoff 
point for statistical significance. Data for each dependent variable is reported as mean + 
SEM.  
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RESULTS  
Mechanism of Action of the Isolated Compound 
i. Dose Response  
Fig. 5.1 denotes the dose-response relationship between the isolated active 
compound and α-glucosidase enzyme inhibition. At 0.1 mg/ml, 0.25 mg/ml and 0.5 
mg/ml of the active compound, 23.42%, 45.92% and 67.73% inhibition of the enzyme 
complex were observed (P < 0.05, r2 = 0.95), respectively, indicating a dose-dependent 
relationship. The linear curve had a slope of 130.82 and intercept of 6.4689, from which 
IC50 was derived and determined to be 0.33 mg/ml. 
ii. Enzyme Specificity 
ii.a. Pancreatic α-Amylase Inhibition 
Fig. 5.2 reveals that α-amylase, assayed utilizing an α-amylase inhibition assay, 
was active in the presence of the isolated compound, in comparison to the standard (P 
< 0.05). The isolated compound hence inhibits α-glucosidase but not α-amylase 
enzyme, at 0.5 mg/ml.  
ii.b. Single α-Glucosidase Enzyme Inhibition 
Sucrase, maltase and isomaltase activity was observed separately utilizing α-
glucosidase enzyme extract with the substrates being sucrose, maltose, and 
isomaltose, respectively. As shown in Fig. 5.3, the active sub-fraction appears to exert 
its α-glucosidase-inhibiting activity by predominantly inhibiting maltase and isomaltase, 
among the 3 enzymes that make up the enzyme complex. It exerted 48%, 49% and 
16% inhibition of isomaltase, maltase and sucrase, respectively. The standard 
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(acarbose), under the same conditions, predominantly inhibited maltase and sucrase, 
and only showed little isomaltase inhibition.  
Antioxidant Activity of Active Compound 
i. DPPH Radical Scavenging 
Antioxidant capacity of the active compound was evaluated by DPPH radical 
scavenging assay. While 0.5 mg/ml of the compound exhibited nearly no quenching 
activity (1.59%), 1 and 5 mg/ml of the compound scavenged 11.09% and 34.87% of the 
DPPH radicals in the reaction at 120 min, respectively. Percent DPPH scavenging per 
tested compound concentration is presented in Fig. 5.4.  
ii. Oxygen Radical Absorbance Capacity (ORACFL) 
The active compound’s antioxidant capacity was also evaluated via the ORACFL 
assay which enabled the estimation of the scavenging capability of the active compound 
against peroxyl radicals (AAPH). As depicted in Fig. 5.5, the compound appears to 
possess a notable oxygen radical scavenging activity, namely by surpassing the 
standard at equal concentrations. Trolox, a known scavenger of the peroxyl radical, was 
used as the standard. At 200 µM, the ORACFL of the active compound was 1.9 fold that 
of the standard. At 40 µM, the ORACFL of the active compound was 2.9 fold that of the 
standard. 
iii. ABTS Radical Cation Neutralization 
 The radical scavenging capacity of the active compound was further assessed 
utilizing an ABTS radical cation. The compound surpassed the standard in cation 
neutralization. At 31 minutes, 17.67%, 22.24% and 32.73% neutralization were 
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observed with the standard, sample at 200 µM and sample at 400 µM, respectively. 
ABTS cation neutralization by the active compound is presented in Fig. 5.6. 
Stability of the Active Compound 
i. Thermal Stability  
Stability of the active sub-fraction at 37 ºC is previously established given that the 
reaction is carried out at this temperature. In this test, the sub-fraction’s activity at room 
temperature was used as a reference to assess its activity at 50-121 ºC. At 50 ºC, no 
loss of activity was observed. At 80 and 100 ºC, 6.35% and 11.63 % loss of activity was 
observed, respectively. The greatest loss of activity was observed at 121 ºC, where the 
sub-fraction exhibited a 20.3% activity loss. Results are displayed in Fig. 5.7, indicating 
that the active sub-fraction is thermally stable. 
ii. pH Stability 
Table 5.1 represents activity of the active sub-fraction following treatment with 
buffers at a wide pH range. The greatest loss of activity (36.6%) was seen at a pH of 2, 
and activity loss ranging from 6% to 21% was observed at the pH range of 3 to 6. At 
basic pH levels, the activity of the sub-fraction appeared to increase by 4.7% and 10.5% 
at pH levels of 8 and 9, respectively, and decrease by 3% at pH level of 10. 
iii. Shelf-Life and Best Storage Conditions 
At all storage conditions, no loss of activity was observed with the isolated 
compound, when tested at 3 and 6 months, except when stored in the light (61% loss of 
activity at 3 months). However, at 8 months, a complete loss of activity was observed. 
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Cytotoxicity of the Isolated Compound 
Fig. 5.8 represents the results of MTS assay characterizing cell viability in 
presence of two different concentrations of the active compound. Sixty percent 
confluent NIH/3T3 cells were incubated with the compound at 25 and 50 µg/ml. At 25 
µg/ml, 87.06% of cell viability was maintained, whereas 90.6% viability was observed at 
50 µg/ml. Cytotoxicity was assessed by comparing cell viability in solvent control and 
treatment wells to that of wells containing cells and growth media only. When assessing 
the effect of the compound with respect to the solvent control, 90.55% and 90.03% cell 
viability are observed with 25 µg/ml and 50 µg/ml of the compound, respectively. 
DISCUSSION 
Mammalian starch digestion takes place primarily in the small intestine through 
the action of α-amylase, resulting in both linear maltose and branched isomaltose 
oligosaccharides that are additionally hydrolyzed by α-glucosidases to yield glucose [50-
52]. It was hence necessary to find out whether the active compound also exhibits a 
non-specific α-amylase inhibition, a problem previously reported with α-glucosidase 
inhibitors [36]. For instance Acarbose, the most widely acknowledged α-glucosidase 
inhibitor, produces undesirable gastrointestinal side effects such as flatulence and 
diarrhea due to this property [49, 56, 57]. The current finding indicating that the 
compound is not active against pancreatic α-amylase will have strong implications on 
the safety of the compound if it were to be recommended for human consumption in the 
future, as it likely eliminates concerns of gastrointestinal side effects. Also, mammalian 
intestinal α-glucosidase is actually a complex comprised of three individual enzymes:  
sucrase, maltase and isomaltase [36]. One of our goals was also to determine which 
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moiety in the complex is inhibited by the isolated compound, if not all 3 enzymes. While 
Acarbose inhibits maltase and sucrase, [125], our results suggested that the active sub-
fraction (hence the active compound) predominantly inhibits the maltase and isomaltase 
moieties of intestinal α-glucosidase. Furthermore, the compound appears to exhibit a 
dose-dependent inhibition of the enzyme complex, a known characteristic of acarbose 
[126]. The half maximal inhibitory concentration (IC50) of the compound was determined 
to be 0.33 mg/ml, suggesting that this compound may serve as a lead compound in the 
future development of a therapeutic agent. IC50 is a measure of the effectiveness of a 
compound in inhibiting biological or biochemical function. It represents the concentration 
of a drug that is required for 50% inhibition in vitro.  It is commonly used as a measure 
of antagonist drug potency in pharmacological research [127]. Although the IC50 of our 
pure compound is 6.6 times higher than that of Acarbose (50 µg/ml) under our assay 
conditions, this compound is natural, food-derived and possesses the advantage of 
specificity to α-glucosidases. These specificity and method of action properties lead to 
the proposition that the GPE-derived active compound will effectively and specifically 
reduce the amount and rate of carbohydrate digestion, without the risk of 
gastrointestinal discomfort. These characteristics will surely require verification in vivo.  
It is important to note that further mechanism of action testing was limited by the 
inability to re-isolate the active compound. Detailed mode of action tests are often 
required before a substance is recommended for human consumption. Measurements 
of the rates of catalysis at different concentrations of substrate and inhibitor often 
answer this question [128]. These tests were not completed due to the unavailability of 
sufficient amounts of the isolated active compound. Bioactivity-guided fractionation 
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commonly yields minute amounts of bioactive components [129], often sufficient for a 
limited number of tests. Furthermore, when a bioactive component is isolated, it is not 
uncommon for its re-isolation to fail even when an identical protocol is employed. Also, 
the process of extract fractionation can lead to a reduction or loss of biological activity 
by compound break-down, which may result in the re-isolation of an inactive or less 
active component [61]. Due to the fact that plant material-derived bioactive compounds 
often reside in multi-component blends, their separation and isolation remains a 
challenge [91]. 
Our recent finding associating mammalian intestinal α-glucosidase inhibition with 
antioxidant capacity of 6 red wine grape pomace extracts (Chapter 3) sparked an 
interest in investigating the presence of this trend in the isolated active compound. In 
fact, the compound appeared to possess a remarkable antioxidant activity. Although its 
DPPH radical quenching capacity was not as prominent as that of the crude Tinta Cão 
GPE at similar concentration and conditions (Chapter 3), the active compound still 
scavenged 35% of the radical in the medium. On the other hand, ORACFL values of the 
active compound were impressive. At the tested concentrations, it appeared to be at 
least 1.9-fold more active than trolox, a known potent scavenger of the peroxyl radical, 
at identical concentrations. When incubated with the ABTS radical cation, the 
compound also showed a potent inhibition, outweighing the standard trolox at a similar 
concentration. These striking findings suggest that the isolated compound is a novel 
antioxidant compound that has not been previously investigated for this property, to our 
knowledge. These results may partly explain the previously observed correlation 
between α-glucosidase inhibition and antioxidant capacity. Furthermore, antioxidant 
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activity exhibited by a compound found to potently inhibit α-glucosidase enzyme 
function may have strong implications on diabetes management. Oxidative stress has 
long been regarded as a leading factor in the progression of diabetes and development 
of its chronic, mostly irreversible complications [130-132].  
Glycosides such as anthocyanins are known to be sensitive to high temperatures 
upon which they readily degrade or polymerize with other compounds in the medium 
[133]. It was hence anticipated that our GPE-derived active compound may lose activity 
upon boiling, given that it is a glycoside. Surprisingly, there was no significant loss of 
activity upon exposure of the active sub-fraction to high temperatures, indicating that the 
compound will likely withstand food processing temperatures if applied as a functional 
food in the future.  
Although plant-derived phenolic compounds have been reported to be more 
stable in acidic than alkali media [134, 135], our findings suggest that the isolated 
compound exhibits up to 37% activity loss at very low pH levels but remains active at 
basic pH levels. The compound’s stability at high pH levels may have important 
implications in its applications in food. Alkali treatment has become a common 
procedure in food processing, utilized for multiple purposes, ranging from protein 
recovery from cereals to the destruction of microorganisms [136]. 
Despite the current compound’s stability under room temperature, fridge and 
freezer storage conditions for up to 6 months, it appears to lose activity after 8 months 
of storage. Moreover, it displays a clear instability upon light exposure. These features 
are not uncommon with plant-derived bioactives in general, and phenolic compounds in 
specific. These compounds are sensitive to light, which facilitates degradation reactions 
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[137]. Instability is often encountered with natural medicine, and while there may not be 
a wide range of options to overcome this limitation, scientists continue to invest in 
studying and developing a bioactive compound within the scope of its stability. 
Cytotoxicity testing is fundamental in the process of drug discovery. It is essential 
to conduct cytotoxicity studies to ensure that the product under investigation is not toxic 
to animal cells [61, 138]. The current cytotoxicity results imply that the isolated 
compound is not cytotoxic to cells at the tested concentrations. To note, due to shortage 
of sample, only two- low concentrations- were selected for this test. However, given that 
cell viability was almost identical when comparing the wells containing 25 µg/ml of 
sample to those containing 50 µg/ml, it appears that cytotoxicity levels did not increase 
upon doubling sample concentration. Hence, it may be safe to assume that the 
compound is likely not cytotoxic at higher concentrations. This implies the likelihood that 
the compound is safe for human consumption, but animal testing is recommended prior 
to clinical testing. 
Conclusion 
Red wine grapes, specifically Tinta Cão, are a promising bioresource for the 
development of an effective and likely safe to consume α-glucosidase inhibitor for the 
management of diabetes, providing a dual benefit considering antioxidant capacity. At 
least one component, D-Glucopyranose6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, has 
proven to possess these properties. Pre-clinical and clinical investigations are 
necessary future steps to validate these findings in vivo. Natural products continue to 
serve as drug leads and given the unlimited availability of plants, it is imperative to 
invest in research investigating the bioactive properties of plant components.  
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FIGURES 
Fig. 5.1. Percent Inhibition of α-Glucosidase by the Isolated Compound at Different 
Concentrations. Enzyme activity was determined by measuring p-nitrophenol release 
from pNPG at 405 nm. The isolated compound was assayed at 0.1, 0.25 and 0.5 mg/ml. 
Points marked with different letters are significantly different (p<0.05). 
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Fig. 5.2. Percent Inhibition of Pancreatic α-Amylase by the Isolated Compound. Enzyme 
activity was determined by measuring maltose release from starch at 540 nm. Acarbose 
(50 µg/ml) is the standard. Active compound was assayed at 0.5 mg/ml. Result is 
compared with α-glucosidase inhibition (p-nitrophenol release from pNPG at 405 nm) at 
similar sample and standard concentrations. Asterisk indicates significant difference 
compared to standard (p<0.05). 
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Fig. 5.3. Inhibition of Single α-Glucosidase Complex Enzymes by the Active Sub-
Fraction. Enzyme activity was determined by measuring glucose release from 
oligosaccharides at 505 nm. Active sub-fraction (5 mg/ml) was incubated with maltose, 
isomaltose and sucrose, to estimate the activity of maltase, isomaltase and sucrase, 
respectively. Standard, acarbose, was subjected to similar testing. 
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Fig. 5.4. Percent DPPH Scavenging per Active Compound Concentration. Scavenging 
capacity was measured at 500 nm using 2,2-Di(4-tert-octylphenyl)-1-picrylhydrazyl 
(DPPH) radical. The reaction was conducted for 120 min. Control, identical reaction 
containing the sample solvent. Different letters represent significant difference (p<0.05). 
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Fig. 5.5. Oxygen Radical Absorbance Capacity (ORACFL) of the Isolated Active 
Compound. ORACFL was determined using 2,2′-Azobis(2-amidinopropane) 
dihydrochloride (AAPH) as a peroxyl radical generator. Data is presented as antioxidant 
power in relative fluorescence units (RFU). Active compound was compared to standard 
(trolox) at equal concentrations. Asterisk indicates significant difference compared to 
standard (p<0.05). 
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Fig. 5.6. Percent ABTS Cation Neutralization by the Active Compound. Neutralization of 
the 2,2′-azinobis(3-ethylbenzothiazoline -6-sulfonic acid) (ABTS) reactive cation was 
measured at 405 nm. The reaction was conducted for 31 min. Control, identical reaction 
containing the sample solvent. Different letters represent significant difference (p<0.05). 
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Fig. 5.7. Thermal Stability of the Active Sub-Fraction. Enzyme activity was determined 
by measuring p-nitrophenol release from pNPG at 405 nm. The active sub-fraction was 
assayed at 1 mg/ml after heat treatment at 50, 80, 100 and 121 ºC. Percent enzyme 
inhibition was assessed in comparison to untreated sample (room temperature), 
denoted as RT. 
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Table 5.1. pH Stability of the Active Sub-Fraction. Enzyme activity was determined by 
measuring p-nitrophenol release from pNPG at 405 nm. The sub-fraction was assayed 
at 0.5 mg/ml after treatment with buffers at pH 3, 4, 5, 6, 8, 9 and 10. Increase/reduction 
in enzyme inhibiting activity was assessed in comparison to untreated sample (pH 7). 
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pH Level Maintained Activity (%) 
2 63 
3 79 
4 94 
5 83 
6 92 
7 (reference) 100 
8 105 
9 110 
10 97 
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Fig. 5.8. Cytotoxicity of the Isolated Compound. NIH/3T3 cells were incubated with the 
compound at 25 and 50 µg/ml for 72 h. Respective solvent controls are 2.5% and 5% 
methanol, denoted as Control. CellTiter 96 AQueous One Solution Reagent was utilized 
to quantify cell viability at 485 nm.  
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Table 5.2. Summary of the Active Compound Applicability Assessment. The isolated 
compound appears to inhibit α-glucosidase and not α-amylase. Furthermore, it is a 
dose-dependent inhibition, exerted by specifically inhibiting the maltase and isomaltase 
moieties of α-glucosidase. The compound also possesses an impressive antioxidant 
capacity. In terms of stability, it was shown to withstand temperature extremes but lose 
activity upon prolonged storage and prolonged exposure to light, and exhibit a partial 
loss of activity upon exposure to very acidic media. Lastly, at 25 and 50 µg/ml, the 
active compound was not cytotoxic to cells, proven by observing up to 90% cell viability. 
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Parameter 
 
 
Result 
Dose-Dependent Yes 
Specificity Maltase, Isomaltase 
Inhibits α-Amylase No 
Antioxidant Property Yes 
Heat Stable Yes 
pH Stable Yes 
Shelf Life < 8 months 
Storage Dark 
Cytotoxic No 
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Summary and Future Directions 
Study 1: The dramatic rise in obesity has led to a surge in type 2 diabetes rates, 
increasing illness, disability and mortality worldwide. Research aiming for the 
development of antidiabetic agents is hence on the rise. A now commonly studied target 
for diabetes and prediabetes management is the control of post-prandial hyperglycemia, 
as opposed to the traditional goal of targeting fasting hyperglycemia. This can be 
achieved by controlling carbohydrate digestion and absorption, and one method is 
inhibiting carbohydrate-digesting enzymes like α-glucosidase. We have previously 
reported that a red wine grape pomace extract (GPE) had the strongest inhibitory 
activity among hundreds of screened plant extracts. In the current study, a screening of 
six red wine GPEs (Chambourcin, Merlot, Norton, Petit Verdot, Syrah and Tinta Cão) 
indicated that the Tinta Cão variety possesses the strongest α-glucosidase inhibiting 
capacity. Antioxidant quantification in these grape varieties revealed an interesting 
trend: varieties with stronger α-glucosidase inhibitory capacity had a higher antioxidant 
content and ability. This prompted HPLC antioxidant profiling of the pomace samples. 
The 15 known antioxidants that appeared to vary in concentration among the 6 varieties 
were not able to suppress α-glucosidase activity, suggesting that the profiled antioxidant 
compounds are not in charge of the observed enzyme inhibition trend. Although the 
components responsible for the observed functions were not identified, the current 
results do reveal high antioxidant content/activity that strongly correlates with α-
glucosidase inhibition. These promising findings may provide a foundation for the future 
use of grape pomace for the potential isolation and development of α-glucosidase 
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inhibitor for diabetes management. Further investigation is required to validate and 
optimize this property.  
Future Directions: Having observed considerable differences in bioactivity among six 
varieties of grape pomace, it would be beneficial in the future to screen a wider range of 
grape varieties. The preparation of the enzyme in pure form as opposed to using an 
enzyme-rich extract would also generate more reliable and reproducible results. Lastly, 
antioxidant profiling would be more informative if more antioxidant standards are 
included, thus covering a wider variety of antioxidants. These strategies will provide a 
more confident foundation for the potential of utilizing GPEs for the development of an 
α-glucosidase inhibitor. However, to progress with the current results, the components 
in Tinta Cão GPE responsible for the observed activity must be identified. 
Study 2: While diabetes rates continue to rise overwhelmingly, the main concern in 
treating diabetes is glycemic control. This is typically achieved by widely available oral 
medications as well as insulin and other injectables. While reliable in achieving short-
term glycemic control, they often come with side effects and fail at certain points in time. 
Even agents targeting post-prandial hyperglycemia (as opposed to fasting 
hyperglycemia), such as Acarbose, appear to exert a non-specific α-amylase inhibition 
besides inhibiting α-glucosidases, generating undesirable gastrointestinal side effects. It 
therefore appears that currently available antihyperglycemic medications are insufficient 
to contain the problem. This brings about the need to explore novel agents. Among 
many scientific investigations searching for natural α-glucosidase inhibitors in the last 
decade, our investigation involving GPEs (study 1) yielded promising results prompting 
further testing to identify the GPE components responsible for the observed activity. An 
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extract is a complex combination of compounds and the search for a specific compound 
or group of compounds typically requires a series of bioactivity guided fractionation 
steps. In the current study, these steps were followed, yielding an active α-glucosidase 
inhibiting GPE fraction, a sub-fraction, and an active pure compound that was 
determined  to be D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}. The 
isolation and identification of this compound may be a giant step forward for the future 
development of a natural α-glucosidase inhibitor from Tinta Cão GPE to potentially use 
for diabetes management and prevention. 
Future Directions: Bioassay guided fractionation is a tedious process that must be 
carefully planned. In our study, we ran into the problem of insufficient amount of isolated 
compound. In the future, it is important to plan the separation with this point in mind. 
Separating large amounts of extracts surely involves magnified waste and cost, 
however, insures the isolation of a sufficient amount of the compound of interest. Also, 
while only the most active fraction was fractionated into sub-fractions, in the future it 
may be beneficial to attempt to fractionate the fraction that ranks next in activity (H2O 
fraction in this study) which may have reduced the limitations related to chemical 
characteristics. However, to further develop the current results, D-Glucopyranose 6-
{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate} must be tested for applicability as a potential 
functional food. 
Study 3: When an agent is determined to possess a health-promoting bioactivity, it has 
to meet safety and stability measures before it is recommended for human 
consumption. The problem of instability is not uncommon with natural products. This 
makes it necessary to determine whether the product is stable under environmental 
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conditions that will likely be faced before and throughout consumption, such as storage, 
pH and temperature changes. It is also imperative to evaluate the safety of the product 
for human consumption. Cytotoxicity tests usually provide reliable information on 
whether the product will be expected to harm animal cells or not. In regards to α-
glucosidase inhibition, another safety measure to take into consideration relates to 
possible side effects, given the nature of present inhibitors. It is important to rule out a 
non-specific α-amylase inhibition which in turn indicates the likelihood that no 
gastrointestinal side effects will be encountered. Alongside testing for enzyme 
specificity, inhibition mode is necessary information for the development of the product 
into a commercial bioactive agent. This study provided valuable inference on these 
aspects. D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate} appears to be 
fairly stable in terms of storage and environmental conditions, with minor limitations that 
can be taken into consideration in future applications. Also, it is likely safe for human 
consumption based on the negative cytotoxicity results and specificity to α-glucosidase, 
to which it is a dose-dependent inhibitor. Interestingly, this compound also exhibits a 
notable antioxidant capacity, which may partly explain the trend observed in study 1, 
and may represent a novel antioxidant compound. These results are fundamental for 
the future development of a natural, food-derived supplement for diabetes prevention 
and treatment, with the dual benefit of α-glucosidase inhibition and antioxidant activity. 
Future Directions: Although the current results provide valuable information on the 
applicability of Tinta Cão GPE-derived D-Glucopyranose 6-{(2E)-3-(4-
Hydroxyphenyl)prop-2-enoate} as a functional food component, further measures of 
stability could be tested, such as photostability, compatibility with different storage 
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containers, storage form, ability to withstand simulated digestion, etc. Stability can 
further be understood by analyzing active compounds via NMR and MS to detect 
structural changes. Also, enzyme kinetics must be employed to reveal the mechanism 
of action. Moreover, cytotoxicity testing at higher concentrations may provide more 
relevant data. It is also important to conduct further measures of antioxidant capacity, 
namely more antioxidant assays (scavenging of additional radicals, lipid peroxidation 
inhibition, etc) and preferably analyze a wide range of known antioxidants for 
comparison, given the impressive antioxidant activity the isolated active compound 
appears to posses. However, to apply the current results, further testing is required prior 
to human consumption recommendation. First, pre-clinical testing should take place. 
This is achieved through the administration of the product to relevant animal models, for 
example diabetic mice/rats. Of interest, in addition to the effect on postprandial 
hyperglycemia, is the product’s antioxidant effects in vivo, which should also be 
evaluated via relevant assays (ferric reducing ability of plasma, lipid peroxidation, 
inflammatory markers, etc). If the pre-clinical study validates the in vitro results with 
minimal to no side effects, then clinical testing is recommended. In a clinical test, human 
subjects with pre-diabetes will be observed for the effects of ingesting different doses of 
the product. Safety and efficacy of the product will render it appropriate for 
consideration for commercial development. These investigations will have very 
important implications given the current prevalence of diabetes and the urgent need to 
find alternative methods to control and prevent it. 
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ABSTRACT 
ISOLATION AND CHARACTERIZATION OF NATURAL α-GLUCOSIDASE 
INHIBITORS FROM ANTIOXIDANT RICH RED WINE GRAPES (VITIS VINIFERA) 
 
by 
HODA KADOUH 
May 2014 
Advisor: Dr. Kequan Zhou 
Major: Nutrition and Food Science 
Degree: Doctor of Philosophy 
Background: Diabetes is currently a global public health problem affecting 
people at all ages. Dietary antioxidants have been associated with a reduced risk of 
type 2 diabetes. Grape pomace contains considerable amounts of polyphenols and it 
has been reported to exhibit an inhibitory activity against alpha- glucosidases. Alpha-
glucosidases, in turn, play a major role in controlling starch digestion and therefore 
postprandial blood glucose, a target for diabetes management.  
Objective: This study aims to investigate the anti-diabetes potential of a 
selection of six grape pomaces and prepare and purify active components in the active 
variety that specifically inhibit intestinal α-glucosidases. The study was also designed to 
evaluate the applicability of the isolated active components as natural inhibitors of α-
glucosidases.  
Methods: Chambourcin, Merlot, Norton, Petit Verdot, Syrah and Tinta Cão red 
wine grape pomace extracts were assessed for their rat intestinal α-glucosidase 
inhibiting activity and antioxidant properties via biochemical assays and UV detection. 
Then, the grape pomace variety shown to potently inhibit the enzyme was subjected to 
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bioactivity-guided fractionation and the isolated active component was identified via 
analytical chemistry techniques. The characterized compound was then tested for 
functional food applicability via stability, enzyme specificity and cytotoxicity testing.  
Results: Tinta Cão grape pomace extract was the most potent α-glucosidase 
inhibiting variety and possessed a remarkable antioxidant activity, both properties of 
which appeared to be correlated.  HPLC analysis did not yield an antioxidant 
responsible for the observed trend. Hence, bioactivity-guided fractionation of the extract 
was pursued, yielding a pure active compound that was determined to be D-
Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, which also exhibited a 
strong antioxidant activity. Further testing indicated that the compound inhibits α-
glucosidase and not α-amylase, and specifically inhibits the maltase and isomaltase 
moieties of α-glucosidase, in a dose-dependent fashion. The compound was fairly 
stable under different environmental and storage conditions, and it was also not 
cytotoxic to animal cells. 
Conclusion: Red grape pomace, namely Tinta Cão, is a promising bioresource 
for the future development of a food-derived antidiabetic agent. At least one component, 
D-Glucopyranose 6-{(2E)-3-(4-Hydroxyphenyl)prop-2-enoate}, isolated from Tinta Cão 
grape pomace appears to potently and specifically inhibit mammalian intestinal α-
glucosidases while exhibiting a notable ability to quench free radicals. It may thus 
represent an alternative future strategy for diabetes management and a novel 
antioxidant compound. Pre-clinical and clinical testing will validate the obtained results 
in vivo.  
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